CDAR2\_IG\_HAIRPT\_R4\_D2\_V4\_HV\_Appendix



**HL7 CDA® R2 Implementation Guide:**

**NHSN Healthcare Associated Infection (HAI) Reports**

**Release 4, STU 2 - US Realm**

**Volume 4 – Appendix:**

**Hemovigilance (HV)**

**Subset For Implementers**

July 2022

**HL7 STU**

**Sponsored by:  
Structured Documents Work Group**

**National Healthcare Safety Network (NHSN)**

Copyright © 2022 Health Level Seven International ® ALL RIGHTS RESERVED. The reproduction of this material in any form is strictly forbidden without the written permission of the publisher. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. Pat & TM Off**.**

Use of this material is governed by HL7's [**IP Compliance Policy**](http://www.hl7.org/legal/ippolicy.cfm?ref=nav).

**IMPORTANT NOTES:**

HL7 licenses its standards and select IP free of charge. **If you did not acquire a free license from HL7 for this document,** you are not authorized to access or make any use of it. To obtain a free license, please visit http://www.HL7.org/implement/standards/index.cfm.

**If you are the individual that obtained the license for this HL7 Standard, specification or other freely licensed work (in each and every instance "Specified Material")**, the following describes the permitted uses of the Material.

**A. HL7 INDIVIDUAL, STUDENT AND HEALTH PROFESSIONAL MEMBERS,** who register and agree to the terms of HL7’s license, are authorized, without additional charge, to read, and to use Specified Material to develop and sell products and services that implement, but do not directly incorporate, the Specified Material in whole or in part without paying license fees to HL7.

INDIVIDUAL, STUDENT AND HEALTH PROFESSIONAL MEMBERS wishing to incorporate additional items of Special Material in whole or part, into products and services, or to enjoy additional authorizations granted to HL7 ORGANIZATIONAL MEMBERS as noted below, must become ORGANIZATIONAL MEMBERS of HL7.

**B. HL7 ORGANIZATION MEMBERS,** who register and agree to the terms of HL7's License, are authorized, without additional charge, on a perpetual (except as provided for in the full license terms governing the Material), non-exclusive and worldwide basis, the right to (a) download, copy (for internal purposes only) and share this Material with your employees and consultants for study purposes, and (b) utilize the Material for the purpose of developing, making, having made, using, marketing, importing, offering to sell or license, and selling or licensing, and to otherwise distribute, Compliant Products, in all cases subject to the conditions set forth in this Agreement and any relevant patent and other intellectual property rights of third parties (which may include members of HL7). No other license, sublicense, or other rights of any kind are granted under this Agreement.

**C. NON-MEMBERS,** who register and agree to the terms of HL7’s IP policy for Specified Material, are authorized, without additional charge, to read and use the Specified Material for evaluating whether to implement, or in implementing, the Specified Material, and to use Specified Material to develop and sell products and services that implement, but do not directly incorporate, the Specified Material in whole or in part.

NON-MEMBERS wishing to incorporate additional items of Specified Material in whole or part, into products and services, or to enjoy the additional authorizations granted to HL7 ORGANIZATIONAL MEMBERS, as noted above, must become ORGANIZATIONAL MEMBERS of HL7.

Please see http://www.HL7.org/legal/ippolicy.cfm for the full license terms governing the Material.

**Ownership.** Licensee agrees and acknowledges that **HL7 owns** all right, title, and interest, in and to the Materials. Licensee shall **take no action contrary to, or inconsistent with**, the foregoing.

**Licensee agrees and acknowledges that HL7 may not own all right, title, and interest, in and to the Materials and that the Materials may contain and/or reference intellectual property owned by third parties (“Third Party IP”). Acceptance of these License Terms does not grant Licensee any rights with respect to Third Party IP. Licensee alone is responsible for identifying and obtaining any necessary licenses or authorizations to utilize Third Party IP in connection with the Materials or otherwise. Any actions, claims or suits brought by a third party resulting from a breach of any Third Party IP right by the Licensee remains the Licensee’s liability.**

Following is a non-exhaustive list of third-party terminologies that may require a separate license:

| **Terminology** | **Owner/Contact** |
| --- | --- |
| Current Procedures Terminology (CPT) code set | American Medical Association https://www.ama-assn.org/practice-management/cpt-licensing |
| SNOMED CT | SNOMED International http://www.snomed.org/snomed-ct/get-snomed-ct or info@ihtsdo.org |
| Logical Observation Identifiers Names & Codes (LOINC) | Regenstrief Institute |
| International Classification of Diseases (ICD) codes | World Health Organization (WHO) |
| NUCC Health Care Provider Taxonomy code set | American Medical Association. Please see www.nucc.org. AMA licensing contact: 312-464-5022 (AMA IP services) |

|  |  |  |  |
| --- | --- | --- | --- |
| Co-Chair: | Calvin Beebe Mayo Clinic [cbeebe@mayo.edu](mailto:cbeebe@mayo.edu) | Co-Chair: | Austin Kreisler Leidos Consultant to CDC/NHSN [duz1@cdc.gov](mailto:duz1@cdc.gov) |
| Co-Chair: | Sean McIlvenna Lantana Consulting Group [sean.mcilvenna@lantanagroup.com](mailto:sean.mcilvenna@lantanagroup.com) | Co-Chair: | Gaye Dolin M.S.N., R.N. Namaste Informatics gdolin@namasteinformatics.com |
| Co-Chair: | Andrew Statler Cerner [andrew.statler@cerner.com](mailto:andrew.statler@cerner.com) | Co-Chair: | Benjamin Flessner Redox [benjamin@redoxengine.com](mailto:benjamin@redoxengine.com) |
| Primary Editor: | Sarah Gaunt Lantana Consulting Group [sarah.gaunt@lantanagroup.com](mailto:sarah.gaunt@lantanagroup.com) | Co-Editor: | Mindy Durrance  Leidos Consultant to CDC/NHSN [mdq1@cdc.gov](mailto:mdq1@cdc.gov) |
| Co-Editor: | Andrea Benin  CDC  [aqb4@cdc.gov](mailto:aqb4@cdc.gov) | Co-Editor: | Joseph Esquibel Leidos Consultant to CDC/NHSN [bwt1@cdc.gov](mailto:bwt1@cdc.gov) |
| Co-Editor: | Dave deRoode Lantana Consulting Group [david.deroode@lantanagroup.com](mailto:david.deroode@lantanagroup.com) | Co-Editor: | Sheila Abner CDC [sha8@cdc.gov](mailto:sha8@cdc.gov) |
| Co-Editor: | Amy Webb Lantana Consulting Group [amy.webb@lantanagroup.com](mailto:amy.webb@lantanagroup.com) | Co-Editor: | Daniel Pollock, M.D. CDC [DPollock@cdc.gov](mailto:DPollock@cdc.gov) |
| Co-Editor: | Zabrina Gonzaga Lantana Consulting Group [zabrina.gonzaga@lantanagroup.com](mailto:zabrina.gonzaga@lantanagroup.com) | Co-Editor: | Beau Bannerman  Lantana Consulting Group [beau.bannerman@lantanagroup.com](mailto:beau.bannerman@lantanagroup.com) |
| Technical Editor: | Diana Wright Lantana Consulting Group [diana.wright@lantanagroup.com](mailto:diana.wright@lantanagroup.com) |  | James Davis Leidos Consultant to CDC/NHSN [mync0@cdc.gov](mailto:mync0@cdc.gov) |

Acknowledgments

This implementation guide was produced and developed by Lantana Consulting Group in conjunction with the Division of Healthcare Quality Promotion in the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) at the Centers for Disease Control and Prevention (CDC). Its development and ultimate deployment is a result of the dedication of the team—led by Daniel A. Pollock, M.D., Surveillance Branch Chief, Division of Healthcare Quality Promotion, NCEZID, CDC—and their support of the development of interoperable data standards for the CDC’s National Healthcare Safety Network (NHSN).

The best standards are those driven by business requirements. A strong set of Healthcare Associated Infection (HAI) surveillance application vendors monitor, evaluate, and test each release of this guide.

Past contributors: The vendors who participated in the 2007-2008 pilot activities of Bloodstream Infection Reports and Surgical Site Infection deserve special thanks and acknowledgment: MedMined™ services from Cardinal Health, EpiQuest, ICPA, Premier, TheraDoc, and Vecna Technologies. Throughout the development of this guide, Marla Albitz provided essential translation of NHSN business and technical requirements so that Kate Hamilton, Bob Dolin, Rick Geimer, and Susan Hardy could turn those requirements into a CDA-compliant specification. Liora Alschuler provided oversight and review. Additional contributors to the DSTU releases have been Jonathan Edwards, Maggie Dudeck, Dawn Sievert, Teresa Horan, Mary Andrus, Melinda Neuhauser, Ruby Phelps, Mindy Durrance, Alicia Shugart, Tygh Walker, Chris Cole, Cindy Gross, and Scott Fridkin (data specifications); Wenkai Li, Pavla Frazier, Gaye Dolin, Margaret Marshburn, Rob Hausam, Sundak Ganesan, and Denny Cordy (vocabulary); Kelly Peterson (database administration); Venu Sarraff (data importation); and Brett Marquard and Lauren Wood (project management and technical editing). We also thank Ted Klein, Cecil Lynch, and Daniel Vreeman for timely issuance of identifiers and codes.

This specification is a set of constraints on existing work, and the extent to which it can accommodate the expressive requirements of HAI reporting over time is a function of the richness of the model on which it is built, the Health Level Seven (HL7) Reference Information Model (RIM) and the RIM document standard, and the Clinical Document Architecture Release 2 (CDA R2). We thank all those who have worked for over a decade to produce these fundamental specifications.

This material contains content from SNOMED CT® (<http://www.ihtsdo.org/snomed-ct/>). SNOMED CT is a registered trademark of the International Health Terminology Standard Development Organisation (IHTSDO).

This material contains content from LOINC® ([http://loinc.org](http://loinc.org/)). The LOINC table, LOINC codes, and LOINC panels and forms file are copyright © 1995-2019, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and available at no cost under the license at <https://loinc.org/kb/license/>.

Contents

[1 Introduction 12](#_Toc99177123)

[1.1 Purpose 12](#_Toc99177124)

[1.2 Audience 12](#_Toc99177125)

[1.3 Organization of the Appendix 12](#_Toc99177126)

[1.3.1 Introductory Material 12](#_Toc99177127)

[1.3.2 CDA Templates and Supporting Material 13](#_Toc99177128)

[1.3.3 Example Instance Identifiers 13](#_Toc99177129)

[2 CDA R2 Background 15](#_Toc99177130)

[2.1 Templated CDA 15](#_Toc99177131)

[2.2 Change Notification Process 16](#_Toc99177132)

[3 Design Considerations 17](#_Toc99177133)

[3.1 Rendering Header Information for Human Presentation 17](#_Toc99177134)

[3.2 Unknown and No Known Information 17](#_Toc99177135)

[3.3 Negating Clinical Statements 21](#_Toc99177136)

[3.4 Summary Document ServiceEvent Codes 21](#_Toc99177137)

[4 Using This Implementation Guide 22](#_Toc99177138)

[4.1 Levels of Constraint 22](#_Toc99177139)

[4.2 Conformance Conventions Used in This Guide 22](#_Toc99177140)

[4.2.1 Templates and Conformance Statements 22](#_Toc99177141)

[4.2.2 Template Versioning 24](#_Toc99177142)

[4.2.3 Open and Closed Templates 25](#_Toc99177143)

[4.2.4 Conformance Verbs (Keywords) 25](#_Toc99177144)

[4.2.5 Cardinality 26](#_Toc99177145)

[4.2.6 Optional and Required with Cardinality 26](#_Toc99177146)

[4.2.7 Vocabulary Conformance 27](#_Toc99177147)

[4.2.8 Data Types 28](#_Toc99177148)

[4.2.9 Succession Management 29](#_Toc99177149)

[4.3 XML Conventions Used in This Guide 29](#_Toc99177150)

[4.3.1 XPath Notation 29](#_Toc99177151)

[4.3.2 XML Examples and Sample Documents 30](#_Toc99177152)

[4.4 Supporting Tools 30](#_Toc99177153)

[4.4.1 Validation 30](#_Toc99177154)

[4.4.2 Generation of Narrative Block 30](#_Toc99177155)

[4.4.3 Display Transforms 31](#_Toc99177156)

[5 Document-Level Templates 32](#_Toc99177157)

[5.1 Healthcare Associated Infection Report 32](#_Toc99177158)

[5.1.1 HAI Population Summary Report Generic Constraints 37](#_Toc99177159)

[5.1.2 Hemovigilance (HV) Summary Report (V2) 43](#_Toc99177160)

[6 Section-Level Templates 46](#_Toc99177161)

[6.1 HAI Section Generic Constraints 46](#_Toc99177162)

[6.1.1 Summary Data Section (HV) (V2) 47](#_Toc99177163)

[7 Entry-Level Templates 51](#_Toc99177164)

[7.1 Blood Product Usage Summary Observation (V2) 51](#_Toc99177165)

[7.2 Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) 55](#_Toc99177166)

[7.3 ISBT Product Code Summary Observation (V2) 58](#_Toc99177167)

[7.4 No Hemovigilance Adverse Reactions Reported This Month Observation 82](#_Toc99177168)

[7.5 No Hemovigilance Incidents Reported This Month Observation 85](#_Toc99177169)

[7.6 Pathogen Reduced Apheresis Platelet Usage Summary Observation 88](#_Toc99177170)

[7.7 Summary Data Observation (HV) 91](#_Toc99177171)

[7.8 Summary Encounter (HV) (V2) 94](#_Toc99177172)

[8 Template Ids in This Guide 101](#_Toc99177173)

[9 Value Sets In This Guide 103](#_Toc99177174)

[10 Code Systems in This Guide 106](#_Toc99177175)

[11 Changes from Previous Version 107](#_Toc99177176)

Figures

[Figure 1: Templated CDA 15](#_Toc99177177)

[Figure 2: nullFlavor Example 18](#_Toc99177178)

[Figure 3: Attribute Required—nullFlavor not allowed 18](#_Toc99177179)

[Figure 4: Allowed nullFlavors When Element is Required—with XML examples 19](#_Toc99177180)

[Figure 5: Unknown Medication Example 19](#_Toc99177181)

[Figure 6: Unknown Medication Use of Anticoagulant Drug Example 20](#_Toc99177182)

[Figure 7: No Known Medications Example 20](#_Toc99177183)

[Figure 8: Value Known—code for value not known 20](#_Toc99177184)

[Figure 9: Value Completely Unknown 21](#_Toc99177185)

[Figure 10: Value Known—code in required code system not known but code from another code system is known 21](#_Toc99177186)

[Figure 11: Context Tables 23](#_Toc99177187)

[Figure 12: Constraints Overview Table Example 23](#_Toc99177188)

[Figure 13: Constraints Format Example 24](#_Toc99177189)

[Figure 14: Versioned Template Change Log Example 25](#_Toc99177190)

[Figure 15: Constraints Format—only one allowed 26](#_Toc99177191)

[Figure 16: Constraints Format—only one like this allowed 26](#_Toc99177192)

[Figure 17: Binding to a Single Code 27](#_Toc99177193)

[Figure 18: XML Expression of a Single-code Binding 28](#_Toc99177194)

[Figure 19: Example Value Set Table 28](#_Toc99177195)

[Figure 20: XML Document Example 29](#_Toc99177196)

[Figure 21: XPath Expression Example 29](#_Toc99177197)

[Figure 22: ClinicalDocument Example 30](#_Toc99177198)

[Figure 23: Software Author Example 37](#_Toc99177199)

[Figure 24: Summary Data Section (HV) (V2) Example 50](#_Toc99177200)

[Figure 25: Blood Product Usage Summary Observation (V2) Example 54](#_Toc99177201)

[Figure 26: Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) Example 57](#_Toc99177202)

[Figure 27: ISBT Product Code Summary Observation Example 81](#_Toc99177203)

[Figure 28: No Hemovigilance Adverse Reactions Reported This Month Observation Example 84](#_Toc99177204)

[Figure 29: No Hemovigilance Incidents Reported This Month Observation 87](#_Toc99177205)

[Figure 30: Pathogen Reduced Apheresis Platelet Usage Summary Example 91](#_Toc99177206)

[Figure 31: Summary Data Observation (HV) Example 93](#_Toc99177207)

[Figure 32: Summary Encounter (HV) (V2) Example 99](#_Toc99177208)

Tables

[Table 1: Required and Optional Sections for Each Document Type 32](#_Toc99177209)

[Table 2: Healthcare Associated Infection Report Constraints Overview 33](#_Toc99177210)

[Table 3: HAI Population Summary Report Generic Constraints Constraints Overview 39](#_Toc99177211)

[Table 4: NHSNPopulationSummaryReportTypeCode 42](#_Toc99177212)

[Table 5: Hemovigilance (HV) Summary Report (V2) Contexts 43](#_Toc99177213)

[Table 6: Hemovigilance (HV) Summary Report (V2) Constraints Overview 44](#_Toc99177214)

[Table 7: HAI Section Generic Constraints Constraints Overview 46](#_Toc99177215)

[Table 8: Summary Data Section (HV) (V2) Contexts 47](#_Toc99177216)

[Table 9: Summary Data Section (HV) (V2) Constraints Overview 48](#_Toc99177217)

[Table 10: Blood Product Usage Summary Observation (V2) Contexts 51](#_Toc99177218)

[Table 11: Blood Product Usage Summary Observation (V2) Constraints Overview 52](#_Toc99177219)

[Table 12: NHSNSummaryBloodProductUsage 53](#_Toc99177220)

[Table 13: Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) Contexts 55](#_Toc99177221)

[Table 14: Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) Constraints Overview 56](#_Toc99177222)

[Table 15: ISBT Product Code Summary Observation (V2) Contexts 58](#_Toc99177223)

[Table 16: ISBT Product Code Summary Observation (V2) Constraints Overview 58](#_Toc99177224)

[Table 17: NHSN Whole Blood Total (1) 63](#_Toc99177225)

[Table 18: NHSN Red Blood Cells/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (3) 63](#_Toc99177226)

[Table 19: NHSN Red Blood Cells/Whole Blood Derived/Irradiated (4) 64](#_Toc99177227)

[Table 20: NHSN Red Blood Cells/Whole Blood Derived/Irradiated and Leukocyte Reduced (6) 64](#_Toc99177228)

[Table 21: NHSN Red Blood Cells/Whole Blood Derived/Leukocyte Reduced (5) 65](#_Toc99177229)

[Table 22: NHSN Red Blood Cells/Apheresis/Not Irradiated or Leukocyte Reduced (8) 65](#_Toc99177230)

[Table 23: NHSN Red Blood Cells/Apheresis/Irradiated (9) 66](#_Toc99177231)

[Table 24: NHSN Red Blood Cells/Apheresis/Leukocyte Reduced (10) 66](#_Toc99177232)

[Table 25: NHSN Plasma/Apheresis/Riboflavin-Treated (36) 67](#_Toc99177233)

[Table 26: NHSN Plasma/Apheresis/Psoralen-Treated (35) 67](#_Toc99177234)

[Table 27: NHSN Plasma/Whole Blood Derived/Riboflavin-Treated (33) 68](#_Toc99177235)

[Table 28: NHSN Plasma/Whole Blood Derived/Psoralen-Treated (32) 68](#_Toc99177236)

[Table 29: NHSN Platelets/Apheresis/Riboflavin-Treated (30) 69](#_Toc99177237)

[Table 30: NHSN Platelets/Apheresis/Psoralen-Treated (29) 69](#_Toc99177238)

[Table 31: NHSN Platelets/Whole Blood Derived/Riboflavin-Treated (27) 70](#_Toc99177239)

[Table 32: NHSN Platelets/Whole Blood Derived/Psoralen-Treated (26) 70](#_Toc99177240)

[Table 33: NHSN Cryoprecipitate (24) 71](#_Toc99177241)

[Table 34: NHSN Plasma/Apheresis/Total (23) 71](#_Toc99177242)

[Table 35: NHSN Plasma/Whole Blood Derived/Total (22) 72](#_Toc99177243)

[Table 36: NHSN Platelets/Apheresis/Irradiated or Leukocyte Reduced (21) 72](#_Toc99177244)

[Table 37: NHSN Platelets/Apheresis/Leukocyte Reduced (20) 73](#_Toc99177245)

[Table 38: NHSN Platelets/Apheresis/Irradiated (19) 73](#_Toc99177246)

[Table 39: NHSN Platelets/Apheresis/Not Irradiated or Leukocyte Reduced (18) 74](#_Toc99177247)

[Table 40: NHSN Platelets/Whole Blood Derived/Irradiated and Leukocyte Reduced (16) 74](#_Toc99177248)

[Table 41: NHSN Platelets/Whole Blood Derived/Leukocyte Reduced (15) 75](#_Toc99177249)

[Table 42: NHSN Platelets/Whole Blood Derived/Irradiated (14) 75](#_Toc99177250)

[Table 43: NHSN Platelets/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (13) 76](#_Toc99177251)

[Table 44: NHSN Red Blood Cells/Apheresis/Irradiated or Leukocyte Reduced (11) 76](#_Toc99177252)

[Table 45: NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated 77](#_Toc99177253)

[Table 46: NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated 77](#_Toc99177254)

[Table 47: NHSN Red Blood Cells/Apheresis/S-303-Treated (41) 78](#_Toc99177255)

[Table 48: NHSN Red Blood Cells/Apheresis/Riboflavin-Treated (42) 78](#_Toc99177256)

[Table 49: NHSN Cryoprecipitate/Psoralen-Treated (44) 78](#_Toc99177257)

[Table 50: NHSN Cryoprecipitate/Riboflavin-Treated (45) 79](#_Toc99177258)

[Table 51: NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma (46) 79](#_Toc99177259)

[Table 52: NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution (47) 80](#_Toc99177260)

[Table 53: NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma (48) 80](#_Toc99177261)

[Table 54: NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution (49) 81](#_Toc99177262)

[Table 55: No Hemovigilance Adverse Reactions Reported This Month Observation Contexts 82](#_Toc99177263)

[Table 56: No Hemovigilance Adverse Reactions Reported This Month Observation Constraints Overview 83](#_Toc99177264)

[Table 57: No Hemovigilance Incidents Reported This Month Observation Contexts 85](#_Toc99177265)

[Table 58: No Hemovigilance Incidents Reported This Month Observation Constraints Overview 86](#_Toc99177266)

[Table 59: Pathogen Reduced Apheresis Platelet Usage Summary Observation Contexts 88](#_Toc99177267)

[Table 60: Pathogen Reduced Apheresis Platelet Usage Summary Observation Constraints Overview 89](#_Toc99177268)

[Table 61: NHSN Pathogen Reduced Apheresis Platelet Usage 90](#_Toc99177269)

[Table 62: Summary Data Observation (HV) Contexts 91](#_Toc99177270)

[Table 63: Summary Data Observation (HV) Constraints Overview 92](#_Toc99177271)

[Table 64: Codes for Hemovigilance (HV) Summary Data 93](#_Toc99177272)

[Table 65: Summary Encounter (HV) (V2) Contexts 94](#_Toc99177273)

[Table 66: Summary Encounter (HV) (V2) Constraints Overview 95](#_Toc99177274)

[Table 67: Template List 101](#_Toc99177275)

[Table 68: Template Containments 102](#_Toc99177276)

[Table 69: Value Sets 103](#_Toc99177277)

[Table 70: Code Systems 106](#_Toc99177278)

# Introduction

Purpose

This appendix is a stand-alone document containing the CDA implementation guidance for the Summary (Denominator) Report dealing with Hemovigilance (HV) data. This report is the Hemovigilance (HV) Summary Report (Denominator).

This appendix contains an informative subset of the templates that are contained in Volume 2 and the purpose of the appendix is as a convenience for implementers who are implementing that subset.

The templates contained in this appendix document are exact copies of the HV templates contained in *HL7 Implementation Guide for CDA® Release 2: NHSN Healthcare Associated Infection (HAI) Reports Release 4, STU 2—US Realm, Volume 2 - Templates and Supporting Material.*

This appendix also contains much of the material presented in the *HL7 Implementation Guide for CDA® Release 2: NHSN Healthcare Associated Infection (HAI) Reports Release 4, STU 2—US Realm, Volume 1 - Introductory Material.*

Audience

The audience for this work is all developers of software systems who want to enable their systems for reporting HAI data to the NHSN.

Organization of the Appendix

Introductory Material

These chapters provide an overview of Clinical Document Architecture (CDA), recent changes to the standard, and information on how to understand and use the CDA templates provided.

* **Chapter 1—Introduction**
* **Chapter 2—CDA R2 Background** contains selected background material on the CDA Release 2 (CDA R2) base standard to aid the reader in conceptualizing the “templated CDA” approach to implementation guide (IG) development.
* **Chapter 3—Design Considerations** describes design considerations and overarching principles that have been developed and applied across the CDA templates in this guide. Material in this section can be thought of as “heuristics”, as opposed to the formal and testable constraints found in chapters 5 through 7 of this guide.
* **Chapter 4—Using This Implementation Guide** describes the rules and formalisms used to constrain the CDA R2 standard. It describes the formal representation of CDA templates, the mechanism by which templates are bound to vocabulary, and additional information necessary to understand and correctly implement the normative content found in chapters 5 through 7 of this guide.

CDA Templates and Supporting Material

* **Chapter 5—Document-Level Templates** defines the report requirements for HAI CDA documents.
  + The Healthcare Associated Infection Report requirements apply to any HAI CDA document. They apply to constraints on the CDA header and sections, and include the requirement that the body be represented by a structuredBody element.
  + The header requirements for population summary reports and for single-person reports differ significantly. HAI defines a generic header template for each of these two sets of requirements. Report-specific templates give additional requirements for each report type in this guide.
* **Chapter 6—Section-Level Templates** defines the generic constraints that apply to all sections along with specific requirements for each section used by the HAI reports in this guide.
* **Chapter 7—Entry-Level Templates** defines clinical statements. Machine processable data are sent in the entry templates. The entry templates are referenced by one or more section templates. Entry-level templates are always contained in section-level templates, and section-level templates are always contained in a document. Requirements for all entries (including organizers) used by the reports in this guide are in alphabetical order.
* **Chapter 8—Template IDs in This Guide** lists the template identifiers used by this guide for HAI reporting to NHSN. These template identifiers are assigned at the document, section, and entry level. Tables list NHSN templates by type and name and by containment.
* **Chapter 9—Value Sets in This Guide** lists all value set names and OIDs used by HAI templates in this guide. Links are provided to external value set sources if appropriate.
* **Chapter 10—Code Systems in This Guide** lists all code system names and OIDs used by HAI templates in this guide, both for value sets and single-value bindings.
* **Chapter 11—Changes From Previous Version** details all changes made in templates for this release.
* **Chapter 12—References**lists documents and sources cited by this guide.
* **Appendices** include a list of acronyms and abbreviations, example instance identifiers, and vocabulary heuristics for code systems and value sets.

Example Instance Identifiers

Much of the initial development of this guide was driven by a pilot project in July 2007. The pilot project used object identifiers (OIDs) assigned to a fictional facility and vendor to illustrate the numbering schemes for which facilities and vendors are responsible.

Except for the example patient identifiers, the example code in this document and the accompanying sample files use these pilot OIDs. Example patient identifiers use the HL7 example OID. In practice, the identifiers will be assigned by facilities and software applications submitting reports to NHSN.

These pilot instance identifiers begin with 2.16.840.1.113883.3.117.1.1.5; HL7 example identifiers begin with 2.16.840.1.113883.19.5. They are used throughout this guide and are documented in the appendix on [Example Instance Identifiers (Non-normative).](#App_Example_Instance_Identifers)

# CDA R2 Background

This IG uses the *HL7 Clinical Document Architecture, Release 2.0 (CDA R2)* as its base standard.[[1]](#footnote-1) CDA R2 is “… a document markup standard that specifies the structure and semantics of ‘clinical documents’ for the purpose of exchange” [CDA R2, Section 1.1]. Clinical documents, according to CDA, have the following characteristics:

* Persistence
* Stewardship
* Potential for authentication
* Context
* Wholeness
* Human readability

CDA defines a header for classification and management, and a document body that carries the clinical record. While the header metadata are prescriptive and designed for consistency across all instances, the body is highly generic, leaving the designation of semantic requirements to implementation.

Templated CDA

CDA R2 can be constrained by mechanisms defined in the “Refinement and Localization”[[2]](#footnote-2) section of the *HL7 Version 3 Interoperability Standards*. The mechanism most commonly used to constrain CDA is referred to as “templated CDA”. In this approach, a library is created containing modular CDA templates such that the templates can be reused across any number of CDA document types, as shown in the following figure.

Figure 1: Templated CDA



Many different kinds of templates may be created. Among them, the most common are:

* **Document-level templates:** These templates constrain fields in the CDA header, and define containment relationships to CDA sections. For example, a History and Physical document-level template might require that the patient’s name be present, and that the document contain a Physical Exam section.
* **Section-level templates:** These templates constrain fields in the CDA section, and define containment relationships to CDA entries. For example, a Physical Exam section-level template might require that the section/code be fixed to a particular LOINC code, and that the section contain a Systolic Blood Pressure observation.
* **Entry-level templates:** These templates constrain the CDA clinical statement model in accordance with real world observations and acts. For example, a Systolic Blood Pressure entry-level template defines how the CDA Observation class is constrained (how to populate observation/code, how to populate observation/value, etc.) to represent the notion of a systolic blood pressure.

A CDA implementation guide (such as this one) includes reference to those templates that are applicable. On the implementation side, a CDA instance populates the template identifier (templateId) field where it wants to assert conformance to a given template. On the receiving side, the recipient can then not only test the instance for conformance against the CDA XML schema, but also test the instance for conformance against asserted templates.

Template identifiers are critical to the validation methods chosen at this time for submissions to the NHSN. NHSN may reject as nonconformant instances that do not conform to the template identifier constraints defined here.

Please reference the NHSN webpage (<http://www.cdc.gov/nhsn/>) to identify which HAI release NHSN currently supports for a given report.

Change Notification Process

CDC maintains an e-mail list of contacts at organizations interested in or responsible for implementations of CDA for HAI reporting to NHSN. To be added to the list, send a request with your contact information to [nhsncda@cdc.gov](mailto:nhsncda@cdc.gov). CDC uses the list for e-mail notifications of changes, including new data requirements. Changes may apply to this guide and to other documents such as business rules that are needed to implement and support CDA for HAI reporting to NHSN. NHSN CDA related information may be found at <https://www.cdc.gov/nhsn/cdaportal/index.html>.

# Design Considerations

Design considerations describe overarching principles that have been developed and applied across the CDA templates in this guide. Material in this section can be thought of as “heuristics”, as opposed to the formal and testable constraints found in chapters 5 through 7 of this guide.

Rendering Header Information for Human Presentation

Metadata carried in the header may already be available for rendering from electronic health records (EHRs) or other sources external to the document; therefore, there is no strict requirement to render directly from the document. An example of this would be a doctor using an EHR that already contains the patient’s name, date of birth, current address, and phone number. When a CDA document is rendered within that EHR, those pieces of information may not need to be displayed since they are already known and displayed within the EHR’s user interface.

Good practice recommends that the following be present whenever the document is viewed:

* Document title and document dates
* Service and encounter types, and date ranges as appropriate
* Names of all persons along with their roles, participations, participation date ranges, identifiers, address, and telecommunications information
* Names of selected organizations along with their roles, participations, participation date ranges, identifiers, address, and telecommunications information
* Date of birth for recordTarget(s)

Unknown and No Known Information

Information technology solutions store and manage data, but sometimes data are not available. An item may be unknown, not relevant, or not computable or measurable, such as where a patient arrives at an Emergency Department unconscious and with no identification.

In many cases, the CDA standard will stipulate that a piece of information is required (e.g., via a **SHALL** conformance verb). However, in most of these cases, the standard provides an “out”, allowing the sender to indicate that the information isn’t known.

Here, we provide guidance on representing unknown information. Further details can be found in the HL7 V3 Data Types, Release One specification that accompanies the CDA R2 normative standard.

A “@nullFlavor” attribute may be used to indicate that information is unknown. Allowable values for populating the attribute give more details about the reason the information is unknown, as shown in the following example.

***Figure*** 2: nullFlavor Example

<!-- CDA requires the consumable element, however NHSN does not

collect further information about the antifungal -->

<consumable>

<manufacturedProduct>

<templateId root="2.16.840.1.113883.10.20.22.4.37"/>

<manufacturedMaterial>

<code nullFlavor="NI"/>

</manufacturedMaterial>

</manufacturedProduct>

</consumable>

Use null flavors for unknown, required, or optional attributes, where allowed per the NHSN protocol:

NI No information. This is the most general and default null flavor.

NA Not applicable. Known to have no proper value (e.g., last menstrual period for a male).

UNK Unknown. A proper value is applicable, but is not known.

ASKU Asked, but not known. Information was sought, but not found (e.g., the patient was asked but did not know).

NAV Temporarily unavailable. The information is not available, but is expected to be available later.

NASK Not asked. The patient was not asked.

MSK There is information on this item available but it has not been provided by the sender due to security, privacy, or other reasons. There may be an alternate mechanism for gaining access to this information.

OTH The actual value is not an element in the value domain of a variable. (e.g., concept not provided by required code system).

The list above contains those null flavors that are commonly used in clinical documents. For the full list and descriptions, see the nullFlavor vocabulary domain in the CDA R2 normative standard.

Unless a nullFlavor is explicitly stated in a constraint in the IG, nullFlavors are not allowed.

Figure 3: Attribute Required—nullFlavor not allowed

**1. SHALL** contain exactly one [1..1] code (CONF:15407).

a. This code **SHALL** contain exactly one [1..1] **@code**="11450-4" Problem List   
 (CodeSystem: LOINC 2.16.840.1.113883.6.1) (CONF:15408).

or

2**. SHALL** contain exactly one [1..1] **effectiveTime/@value** (CONF:5256).

Figure 4: Allowed nullFlavors When Element is Required—with XML examples

1. **SHALL** contain at least one [1..\*] id

2. **SHALL** contain exactly one [1..1] code

3. **SHALL** contain exactly one [1..1] effectiveTime

<entry>

<observation classCode="OBS" moodCode="EVN">

<id nullFlavor="**NI**"/>

<code nullFlavor="**OTH**">

<originalText>New Grading system</originalText>

</code>

<statusCode code="completed"/>

<effectiveTime nullFlavor="**UNK**"/>

<value xsi:type="CD" nullFlavor="OTH">

<originalText>Spiculated mass grade 5</originalText>

</value>

</observation>

</entry>

If a sender wants to state that a piece of information is unknown, the following principles apply:

1. If the sender doesn’t know an attribute of an act, that attribute can be null.

Figure 5: Unknown Medication Example

<entry>

**<text>patient was given a medication but I do not know what it was</text>**

<substanceAdministration moodCode="EVN" classCode="SBADM">

<consumable>

<manufacturedProduct>

<manufacturedLabeledDrug>

<code **nullFlavor="NI"**/>

</manufacturedLabeledDrug>

</manufacturedProduct>

</consumable>

</substanceAdministration>

</entry>

2. If the sender doesn’t know if an act occurred, the nullFlavor is on the act (detail could include specific allergy, drug, etc.).

Figure 6: Unknown Medication Use of Anticoagulant Drug Example

<entry>

<substanceAdministration moodCode="EVN" classCode="SBADM" **nullFlavor="NI">**

**<text>I do not know whether or not patient received an anticoagulant**

**drug</text>**

<consumable>

<manufacturedProduct>

<manufacturedLabeledDrug>

**<code code="81839001" displayName="anticoagulant drug"**

**codeSystem="2.16.840.1.113883.6.96"**

**codeSystemName="SNOMED CT"/>**

</manufacturedLabeledDrug>

</manufacturedProduct>

</consumable>

</substanceAdministration>

</entry>

3. If the sender wants to state ‘no known’, a negationInd can be used on the corresponding act (substanceAdministration, Procedure, etc.)

Figure 7: No Known Medications Example

<entry>

<substanceAdministration moodCode="EVN" classCode="SBADM" **negationInd=”true”>**

**<text>No known medications</text>**

<consumable>

<manufacturedProduct>

<manufacturedLabeledDrug>

**<code code="410942007" displayName="drug or medication"**

**codeSystem="2.16.840.1.113883.6.96"**

**codeSystemName="SNOMED CT"/>**

</manufacturedLabeledDrug>

</manufacturedProduct>

</consumable>

</substanceAdministration>

</entry>

These next examples illustrate additional nuances of representing unknown information in coded fields.

Figure 8: Value Known—code for value not known

<entry>

<observation classCode="OBS" moodCode="EVN">

...

<value xsi:type="CD" nullFlavor="OTH">

<originalText>Spiculated mass grade 5</originalText>

</value>

</observation>

</entry>

Figure 9: Value Completely Unknown

<entry>

<observation classCode="OBS" moodCode="EVN">

...

<value xsi:type="CD" nullFlavor="UNK"/>

</observation>

</entry>

Figure 10: Value Known—code in required code system not known but code from another code system is known

<entry>

<observation classCode="OBS" moodCode="EVN">

...

<value xsi:type="CD" nullFlavor="OTH">

<originalText>Spiculated mass grade 5</originalText>

<translation code="129742005" displayName="spiculated lesion"

codeSystem="2.16.840.1.113883.6.96"

codeSystemName="SNOMED CT"/>/>

</value>

</observation>

</entry>

Negating Clinical Statements

Usually, clinical statements in a CDA document assert positive statements. A procedure element represents a procedure that took place and an observation represents an observation about a patient condition or a laboratory result. In this implementation guide, when negationInd is set to true, it is understood that it negates the act as described by the act’s descriptive properties (including act.code, procedure.effectiveTime, observation.value, etc.) and any of the act’s components, rather than at the level of a specific value in the act. The inert properties such as act.id, act.moodCode, and act.confidentialityCode are not negated and always have the same meaning. In other words, when an act is negated, it indicates that the event as specified did not occur. For example, if the clinical statement is asserting that a wrong procedure has been performed on a certain date and its negationInd is set to true, the whole clinical statement is negated, including any attributes such as the assertion and the effectiveTime. This clinical statement indicates that we are not asserting that this event occurred on this date—there is no assertion that a wrong procedure was performed on this date. For further details and examples, see the definition of Act.negationInd in the HL7 Reference Information Model (RIM), Version 2.07 (the version of the HL7 RIM from which CDA, Release 2 is derived) and the discussion of *Negation Indicators in RIM Classes* in *Core Principles and Properties of V3 Models*.

## Summary Document ServiceEvent Codes

For all the summary reports, the documentationOf/serviceEvent/code element records the type of summary data reported. This corresponds to the NHSN form type. This pattern is similar to that used in C-CDA (all releases) (e.g., Operative Note).

# Using This Implementation Guide

This chapter describes the rules and formalisms used to constrain the CDA R2 standard. It describes the formal representation of CDA templates, the mechanism by which templates are bound to vocabulary, and additional information necessary to understand and correctly implement the normative content found in chapters 5 through 7 of this guide.

Levels of Constraint

The CDA standard describes conformance requirements in terms of three general levels corresponding to three different, incremental types of conformance statements:

* Level 1 requirements impose constraints upon the CDA Header. The body of a Level 1 document may be XML or an alternate allowed format. If XML, it must be CDA-conformant markup.
* Level 2 requirements specify constraints at the section level of a CDA XML document: most critically, the section code and the cardinality of the sections themselves, whether optional or required.
* Level 3 requirements specify constraints at the entry level within a section. A specification is considered “Level 3” if it requires any entry-level templates.

Note that these levels are rough indications of what a recipient can expect in terms of machine-processable coding and content reuse. They do not reflect the level or type of clinical content, and many additional levels of reusability could be defined.

The section libraries for each document type list the required and optional sections.

Conformance Conventions Used in This Guide

Templates and Conformance Statements

Conformance statements within this implementation guide are presented as constraints from Trifolia Workbench, a template repository. An algorithm converts constraints recorded in Trifolia to a printable presentation. Each constraint is uniquely identified by an identifier at or near the end of the constraint (e.g., CONF:86-7345). The digits in the conformance number before the hyphen identify which IG the template belongs to and the number after the hyphen is unique to the owning IG. Together, these two numbers uniquely identify each constraint. These identifiers are persistent but not sequential. Conformance numbers in this guide associated with a conformance statement that is carried forward from a previous version of this guide will carry the same conformance number from the previous version. This is true even if slightly edited. If a conformance statement is entirely new, it will have a new conformance number.

Bracketed information following each template title indicates the template type (section, observation, act, procedure, etc.), the identifier oid or identifier urn, and whether the template is [open or closed](#IG_S_Open_and_Closed_Templates). The identifier oid is the templateId/@root value; all templateIds have an @root value. Newer and/or versioned templates also have an @extension value, which is a date identifying the version of this template; such templates are identified by urn and the HL7 version (urn:hl7ii). The urn identifier includes both the @root and @extension value for the templateId (for example, identifier urn:hl7ii:2.16.840.1.113883.10.20.5.5.41:2014-06-09).

Each section and entry template in this guide includes a context table. The "Contained By" column indicates which templates use this template, and if the template is optional or required in the containing template. The "Contains" column indicates any templates that the template uses.

Figure 11: Context Tables

***XXX: Allergy Problem Act (V2) Contexts***

| **Contained By:** | **Contains:** |
| --- | --- |
| Allergies Section (entries optional) (V2) (optional)  Allergies Section (entries required) (V2) (required) | Allergy - Intolerance Observation (V2)  Author Participation |

Each template also includes a constraint overview table to summarize the constraints in the template.

Figure 12: Constraints Overview Table Example

| **XPath** | **Card.** | **Verb** | **Data Type** | **CONF#** | **Fixed Value** |
| --- | --- | --- | --- | --- | --- |
| observation[identifier: oid:2.16.840.1.113883.10.20.22.4.31] | | | | | |
| @classCode | 1..1 | SHALL |  | XXXX | 2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | XXXX | 2.16.840.1.113883.5.1001 (ActMood) = EVN |
| code | 1..1 | SHALL |  | XXXX |  |
| @code | 1..1 | SHALL |  | XXXX | 2.16.840.1.113883.6.96 (SNOMED CT) = 445518008 |
| value | 1..1 | SHALL | PQ | XXXX |  |
| @unit | 1..1 | SHALL | CS | XXXX | 2.16.840.1.113883.11.20.9.21 (AgePQ\_UCUM) |
| templateId | 1..1 | SHALL |  | XXXX |  |
| @root | 1..1 | SHALL |  | XXXX | 2.16.840.1.113883.10.20.22.4.31 |
| statusCode | 1..1 | SHALL |  | XXXX |  |
| @code | 1..1 | SHALL |  | XXXX | 2.16.840.1.113883.5.14 (ActStatus) = completed |

The following figure shows a typical template’s set of constraints presented in this guide. The next chapters describe specific aspects of conformance statements—open vs. closed statements, conformance verbs, cardinality, vocabulary conformance, containment relationships, and null flavors. The expression “such that it” means, you (**SHALL**/**SHOULD**/**MAY**) have one of those things that look like that, but you can also have another one of those things that look different. The example below states that you must have templateId with a root of 2.16.840.1.113883.10.20.22.4.31 but you can also have other template IDs.

Figure 13: Constraints Format Example

***Age Observation***

[observation: identifier oid:2.16.840.1.113883.10.20.22.4.31(open)]

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass 2.16.840.1.113883.5.6 STATIC) (CONF:XXXX).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: ActMood 2.16.840.1.113883.5.1001 STATIC) (CONF: XXXX).
3. SHALL contain exactly one [1..1] templateId (CONF:XXXX) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.22.4.31" (CONF: XXXX).
4. SHALL contain exactly one [1..1] code (CONF:7615).
   1. This code SHALL contain exactly one [1..1] @code="445518008" Age At Onset (CodeSystem: SNOMED CT 2.16.840.1.113883.6.96 STATIC) (CONF: XXXX).
5. SHALL contain exactly one [1..1] statusCode (CONF: XXXX).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: ActStatus 2.16.840.1.113883.5.14 STATIC) (CONF: XXXX).
6. SHALL contain exactly one [1..1] value with @xsi:type="PQ" (CONF:XXXX).
   1. This value SHALL contain exactly one [1..1] @unit, which SHALL be selected from ValueSet AgePQ\_UCUM 2.16.840.1.113883.11.20.9.21 DYNAMIC (CONF: XXXX).

Template Versioning

A new version of an existing implemenation guide reuses templates from the previous version. During the ballot phase or update phase, templates carry the designation “Published” to indicate the template is unchanged from the previous version or “Draft” to indicate a new or revised template. Substantial revisions to previously published templates are always indicated by “(Vn)” in all cases: ballot-phase, update-phase, and published guides.

If there are no substantive changes to a template that has been successfully published, the template will carry the same templateId/@root (identifier oid) and templateId/@extension as in the previous implementation guide (in the case of older templates, the @extension attribute will not be present). During a new ballot or update phase, “Published” is appended to the main heading for the template to indicate that the template cannot be commented on in the ballot or update. The “Published” designation is removed on final publication versions.

A revised version of a previously published template keeps the same templateId/@root as the previous version, but it is assigned a new templateId/@extension. The notation “(Vn)” (V2, V3, etc.) is also added to the template name. Versions are not necessarily forward or backward compatible. A versioning may be due to substantive changes in the template and/or the fact that a contained template has changed. The “(Vn)” designation is persistent; it appears with that template when it is used in subsequent guides. During a new ballot or update phase, “Draft” is appended to the main heading for the template to indicate that it may be voted on in the ballot or commented on in the update; the “Draft” designation is removed on final publication versions.

A revised version of a template is explicitly linked to the prior version. When a new version appears for the first time in an IG, a detailed change log is automatically generated, a detailed change log is automatically generated. All such changes for a given IG are shown in Chapter 12 “Changes From Previous Version”.

The following figure shows an example of a versioned template: HAI AUR Antimicrobial Resistance Option (ARO) Report (oid:2.16.840.1.113883.10.20.5.31) has versioned to HAI AUR Antimicrobial Resistance Option (ARO) Report (V2) (urn:hl7ii:2.16.840.1.113883.10.20.5.31:2014-06-09).

Figure 14: Versioned Template Change Log Example

| **Change** | **Old** | **New** |
| --- | --- | --- |
| Name | HAI AUR Antimicrobial Resistance Option (ARO) Report | HAI AUR Antimicrobial Resistance Option (ARO) Report (V2) |
| Oid | oid:2.16.840.1.113883.10.20.5.31 | urn:hl7ii:2.16.840.1.113883.10.20.5.31:2014-06-09 |
| CONF #: 1129-30474 Added |  | SHALL contain exactly one [1..1] @extension="2014-06-09" (CONF:1129-30474). |
| CONF #: 1129-21153 Modified | SHALL contain exactly one [1..1] Findings Section in an ARO Report (identifier: oid:2.16.840.1.113883.10.20.5.5.32) | SHALL contain exactly one [1..1] Findings Section in an ARO Report (V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.5.32:2014-06-09) |

Open and Closed Templates

HAI templates are, with one exception, closed templates. This means that the template constraints specify everything that is allowed. In open templates, by contrast, all of the features of the CDA R2 base specification are allowed except as constrained by the templates.

The exception to closed templates in HAI reports is that the structuredBody is open: it may contain sections not specified in this guide. The content of such unspecified sections is not processed by NHSN.

Conformance Verbs (Keywords)

The keywords **shall, should, may, need not, should not,** and **shall not** in this document are to be interpreted as described in the HL7 Version 3 Publishing Facilitator's Guide.[[3]](#footnote-3)

* **shall**: an absolute requirement
* **shall not**: an absolute prohibition against inclusion
* **should/should not**: best practice or recommendation. There may be valid reasons to ignore an item, but the full implications must be understood and carefully weighed before choosing a different course
* **may/need not**: truly optional; can be included or omitted as the author decides with no implications

The keyword "**shall"** allows the use of nullFlavor unless the requirement is on an attribute or the use of nullFlavor is explicitly precluded.

Cardinality

The cardinality indicator (0..1, 1..1, 1..\*, etc.) specifies the allowable occurrences within a document instance. The cardinality indicators are interpreted with the following format “m…n” where m represents the least and n the most:

* 0..1 zero or one
* 1..1 exactly one
* 1..\* at least one
* 0..\* zero or more
* 1..n at least one and not more than n

When a constraint has subordinate clauses, the scope of the cardinality of the parent constraint must be clear. In the next figure, the constraint says exactly one participant is to be present. The subordinate constraint specifies some additional characteristics of that participant.

Figure 15: Constraints Format—only one allowed

1. **SHALL** contain exactly one [1..1] **participant** (CONF:2777).

a. This participant **SHALL** contain exactly one [1..1] **@typeCode**="LOC"   
 (CodeSystem: 2.16.840.1.113883.5.90 HL7ParticipationType)   
 (CONF:2230).

In the next figure, the constraint says only one participant “like this” is to be present. Other participant elements are not precluded by this constraint.

Figure 16: Constraints Format—only one like this allowed

1. **SHALL** contain exactly one [1..1] **participant** (CONF:2777) such that it

a. **SHALL** contain exactly one [1..1] **@typeCode**="LOC" (CodeSystem:

2.16.840.1.113883.5.90 HL7ParticipationType) (CONF:2230).

Optional and Required with Cardinality

The terms *optional* and *required* describe the *lower* bound of cardinality as follows:

*Optional* means that the number of allowable occurrences of an element may be 0; the cardinality will be expressed as [0..1] or [0..\*] or similar. In these cases, the element may not be present in the instance.

*Required* means that the number of allowable occurrences of an element must be at least 1; the cardinality will be expressed as [m..n] where m >=1 and n >=m for example [1..1] or [1..\*]. In these cases, the element must be present in the instance. If an element is required, but is not known (and would otherwise be omitted if it were optional), it must be represented by a null flavor. See “[Unknown and No Known Information”](#IG_S_Unknown_and_No_Known_Information).

Vocabulary Conformance

The templates in this document use terms from several code systems. These vocabularies are defined in various supporting specifications and may be maintained by other bodies, as is the case for the LOINC and SNOMED CT vocabularies.

Note that value-set identifiers (e.g., ValueSet 2.16.840.1.113883.1.11.78 Observation Interpretation (HL7) **DYNAMIC)** do not appear in CDA submissions; they tie the conformance requirements of an implementation guide to the appropriate code system for validation.

Value-set bindings adhere to HL7 Vocabulary Working Group best practices, and include both a conformance verb (**shall**, **should**, **may**, etc.) and an indication of **dynamic** vs. **static** binding. Value-set constraints can be **static**, meaning that they are bound to a specified version of a value set, or **dynamic**, meaning that they are bound to the most current version of the value set. A simplified constraint, used when the binding is to a single code, includes the meaning of the code, as follows.

Figure 17: Binding to a Single Code

**2. SHALL** contain exactly one [1..1] **code** (CONF:15403).

a) This code **SHALL** contain exactly one [1..1] **@code**="11450-4" Problem List

(CONF:15408).

b) This code **SHALL** contain exactly one [1..1] **@codeSystem**="2.16.840.1.113883.6.1"

(CodeSystem: LOINC 2.16.840.1.113883.6.1 **STATIC**) (CONF: 31141).

The notation conveys the actual code (11450-4), the code’s displayName (Problem List), the OID of the codeSystem from which the code is drawn (2.16.840.1.113883.6.1), and the codeSystemName (LOINC).

HL7 Data Types Release 1 requires the codeSystem attribute unless the underlying data type is “Coded Simple” or “CS”, in which case it is prohibited. The displayName and the codeSystemName are optional, but recommended, in all cases.

The above example would be properly expressed as follows.

Figure 18: XML Expression of a Single-code Binding

<code code="11450-4" codeSystem="2.16.840.1.113883.6.1"/>

<!-- or -->

<code code="11450-4" codeSystem="2.16.840.1.113883.6.1"

displayName="Problem List"

codeSystemName=”LOINC”/>

A full discussion of the representation of vocabulary is outside the scope of this document; for more information, see the HL7 V3 Normative Edition 2010[[4]](#footnote-4) sections on Abstract Data Types and XML Data Types R1.

Value set tables are presented below the first template that uses that value set; links are provided in subsequent templates that use the same value set. The value set tables include the value set identifier, a description, a link (where appropriate), and a list of codes in the value set. Ellipses in the last row of value-set members shown indicate that the list is an excerpt and the complete source must be accessed to see all members.

Figure 19: Example Value Set Table

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: Referral Types 2.16.840.1.113883.11.20.9.56  A value set of SNOMED CT codes descending from "3457005" patient referral (procedure).  Value Set Source: https://vsac.nlm.nih.gov | | | |
| **Code** | **Code System** | **Code System OID** | **Print Name** |
| 44383000 | SNOMED CT | 2.16.840.1.113883.6.96 | Patient referral for consultation |
| 391034007 | SNOMED CT | 2.16.840.1.113883.6.96 | Refer for falls assessment (procedure) |
| 86395003 | SNOMED CT | 2.16.840.1.113883.6.96 | Patient referral for family planning (procedure) |
| 306106002 | SNOMED CT | 2.16.840.1.113883.6.96 | Referral to intensive care service (procedure) |
| 306140002 | SNOMED CT | 2.16.840.1.113883.6.96 | Referral to clinical oncology service (procedure) |
| 396150002 | SNOMED CT | 2.16.840.1.113883.6.96 | Referral for substance abuse (procedure) |
| ... |  |  |  |

Data Types

All data types used in a CDA document are described in the CDA R2 normative standard. All attributes of a data type are allowed unless explicitly prohibited by this specification.

Succession Management

CDA-conformant HAI instances use the elements defined in the CDA header (documentId, setId, version number, and relatedDocument/typeCode) to manage replacements and updates of the documents. As with all CDA documents, the ClinicalDocument/id uniquely identifies a document instance (an electronic file). Incremented version numbers identify subsequent versions of the document.

NHSN assigns each participating facility a root OID. The vendor system generates the ClinicalDocument/setId. The vendor is responsible for extending its OID as necessary to support the several unique numbering schemes it must generate; these include document identifiers and facility-generated procedure identifiers.

XML Conventions Used in This Guide

XPath Notation

Instead of the traditional dotted notation used by HL7 to represent RIM classes, this document uses XML Path Language (XPath) notation[[5]](#footnote-5) in conformance statements and elsewhere to identify the Extensible Markup Language (XML) elements and attributes within the CDA document instance to which various constraints are applied. The implicit context of these expressions is the root of the document. This notation provides a mechanism that will be familiar to developers for identifying parts of an XML document.

XPath statements appear in this document in a monospace font.

XPath syntax selects nodes from an XML document using a path containing the context of the node(s). The path is constructed from node names and attribute names (prefixed by a ‘@’) and catenated with a ‘/’ symbol.

Figure 20: XML Document Example

<author>

<assignedAuthor>

...

<code codeSystem='2.16.840.1.113883.6.96'

codeSystemName='SNOMED CT'

code='17561000'

displayName='Cardiologist' />

...

</assignedAuthor>

</author>

In the above example, the code attribute of the code could be selected with the XPath expression in the next figure.

Figure 21: XPath Expression Example

author/assignedAuthor/code/@code

XML Examples and Sample Documents

Extensible Mark-up Language (XML) examples appear in figures in this document in this monospace font. Portions of the XML content may be omitted from the content for brevity, marked by an ellipsis (...) as shown in the example below.

Figure 22: ClinicalDocument Example

<ClinicalDocument xmls="urn:h17-org:v3">

...

</ClinicalDocument>

Within the narrative, XML element (code, assignedAuthor, etc.) and attribute (SNOMED CT, 17561000, etc.) names also appear in this monospace font.

Supporting Tools

Validation

This guide expresses CDA R2 constraints in a technology-neutral formalism. The release when published also provides a non-normative set of Schematron schemas based on the technology-neutral formalism, which can test template conformance.

Schematron is “a language for making assertions about patterns found in XML documents.” The schemas provided for CDA and for this package support two-stage validation. First, the CDA schema CDA.xsd validates the basic structural and semantic requirements of any CDA instance. Second, the IG-specific Schematron schema validates the specific requirements of this package.

Validation services are provided through the NHSN import mechanism and by Lantana Group’s CDA Validator (<https://www.lantanagroup.com/validator/>). The CDA Validator is an online application that validates a CDA document’s conformance to several standards and implementation guides; it includes the Schematron files described above.

Generation of Narrative Block

Clinical documents generated by clinicians for a patient chart can assume an almost infinite set of semantic structures. For this reason, CDA relies on a narrative block (section/text) to convey the comprehensive clinical report, i.e., all the information that a human reader would consider the definitive, legal content of the record. (Human readability and rendering requirements are described in CDA R2, Section 1.2.3. See [References](#IG_S_References).)

In contrast, the structure and semantics of HAI reports to the NHSN are tightly constrained for unambiguous insertion into the NHSN database. Few elements allow unstructured, uncoded narrative. The definitive, human-readable, legal contents of a report can be derived entirely from the CDA titles and coded entries. Therefore, for the convenience of implementers, this project created a transform that derives the narrative block from the CDA entries. Use of this transform is not required; implementers can use local methods to create the CDA narrative block.

Display Transforms

The content required for correct interpretation by a human reader of a compliant instance must be displayable using any CDA stylesheet. Thus, instances conforming to this IG can be viewed using CDA.xsl or any other stylesheet.

In addition, this project has a customized stylesheet that conforms more closely to the display format typical of such records.

# Document-Level Templates

Table 1: Required and Optional Sections for Each Document Type

| Document Type | Required Sections | Optional Sections |
| --- | --- | --- |
| [HAI Population Summary Report Generic Constraints](#D_HAI_Population_Summary_Report_Generic) urn:oid:2.16.840.1.113883.10.20.5.4.28 | N/A | N/A |
| [Healthcare Associated Infection Report](#D_Healthcare_Associated_Infection_Repor) urn:oid:2.16.840.1.113883.10.20.5.4.25 | N/A | N/A |
| [Hemovigilance (HV) Summary Report (V2)](#D_Hemovigilance_HV_Summary_Report_V2) urn:hl7ii:2.16.840.1.113883.10.20.5.49:2016-08-01 | [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) | N/A |

Healthcare Associated Infection Report

[ClinicalDocument: identifier urn:oid:2.16.840.1.113883.10.20.5.4.25 (open)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 1 - US Realm

This template records constraints on all NHSN Healthcare Associated Infection Reports (generic constraints). Further constraints are found in the specialization templates for single-patient and population summary reports, and in the templates for specific report types.  
Annotations before some constraints provide additional information for the implementer.  
Elements required by CDA that are not further constrained in this guide are not presented as HAI-specific constraints.  
Note: The section on “Template Ids in this Guide” includes a containment table showing all the entries within each report type.

Table 2: Healthcare Associated Infection Report Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| ClinicalDocument (identifier: urn:oid:2.16.840.1.113883.10.20.5.4.25) | | | | | |
| realmCode | 1..1 | SHALL |  | [86-18431](#C_86-18431) |  |
| @code | 1..1 | SHALL | CD | [86-18432](#C_86-18432) | US |
| typeId | 1..1 | SHALL |  | [86-18463](#C_86-18463) |  |
| @root | 1..1 | SHALL |  | [86-18464](#C_86-18464) | 2.16.840.1.113883.1.3 |
| @extension | 1..1 | SHALL |  | [86-18465](#C_86-18465) | POCD\_HD000040 |
| templateId | 1..1 | SHALL |  | [86-18460](#C_86-18460) |  |
| @root | 1..1 | SHALL |  | [86-18461](#C_86-18461) | 2.16.840.1.113883.10.20.5.4.25 |
| @extension | 0..0 | SHALL NOT |  | [86-18462](#C_86-18462) |  |
| id | 1..1 | SHALL |  | [86-18466](#C_86-18466) |  |
| @root | 0..1 | MAY |  | [86-18467](#C_86-18467) |  |
| @extension | 0..1 | MAY |  | [86-18468](#C_86-18468) |  |
| code | 1..1 | SHALL |  | [86-18433](#C_86-18433) |  |
| @code | 1..1 | SHALL |  | [86-18434](#C_86-18434) | 51897-7 |
| @codeSystem | 1..1 | SHALL |  | [86-27413](#C_86-27413) | urn:oid:2.16.840.1.113883.6.1 (LOINC) |
| title | 1..1 | SHALL |  | [86-18435](#C_86-18435) |  |
| effectiveTime | 1..1 | SHALL |  | [86-18436](#C_86-18436) |  |
| confidentialityCode | 1..1 | SHALL |  | [86-18437](#C_86-18437) |  |
| @code | 1..1 | SHALL | CD | [86-18438](#C_86-18438) | urn:oid:2.16.840.1.113883.5.25 (HL7Confidentiality) = N |
| languageCode | 1..1 | SHALL |  | [86-18439](#C_86-18439) |  |
| @code | 1..1 | SHALL |  | [86-18440](#C_86-18440) | en-US |
| setId | 1..1 | SHALL |  | [86-18441](#C_86-18441) |  |
| versionNumber | 1..1 | SHALL |  | [86-18442](#C_86-18442) |  |
| recordTarget | 1..\* | SHALL |  | [86-18472](#C_86-18472) |  |
| author | 1..\* | SHALL |  | [86-18473](#C_86-18473) |  |
| custodian | 1..1 | SHALL |  | [86-18443](#C_86-18443) |  |
| assignedCustodian | 1..1 | SHALL |  | [86-18444](#C_86-18444) |  |
| representedCustodianOrganization | 1..1 | SHALL |  | [86-18445](#C_86-18445) |  |
| id | 1..1 | SHALL |  | [86-18446](#C_86-18446) |  |
| @root | 1..1 | SHALL |  | [86-18447](#C_86-18447) | 2.16.840.1.114222.4.3.2.11 |
| legalAuthenticator | 0..1 | SHOULD |  | [86-18474](#C_86-18474) |  |
| relatedDocument | 0..\* | MAY |  | [86-18469](#C_86-18469) |  |
| @typeCode | 1..1 | SHALL |  | [86-18470](#C_86-18470) | urn:oid:2.16.840.1.113883.5.1002 (HL7ActRelationshipType) = RPLC |
| parentDocument | 1..1 | SHALL |  | [86-28401](#C_86-28401) |  |
| id | 1..\* | SHALL |  | [86-28402](#C_86-28402) |  |
| component | 1..1 | SHALL |  | [86-18448](#C_86-18448) |  |
| structuredBody | 1..1 | SHALL |  | [86-18449](#C_86-18449) |  |
| component | 1..\* | SHALL |  | [86-18475](#C_86-18475) |  |

1. SHALL contain exactly one [1..1] realmCode (CONF:86-18431).
   1. This realmCode SHALL contain exactly one [1..1] @code="US" (CONF:86-18432).
2. SHALL contain exactly one [1..1] typeId (CONF:86-18463).
   1. This typeId SHALL contain exactly one [1..1] @root="2.16.840.1.113883.1.3" (CONF:86-18464).
   2. This typeId SHALL contain exactly one [1..1] @extension="POCD\_HD000040" (CONF:86-18465).
3. SHALL contain exactly one [1..1] templateId (CONF:86-18460) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.4.25" (CONF:86-18461).
   2. SHALL NOT contain [0..0] @extension (CONF:86-18462).

CDA requires a ClinicalDocument/id element representing a unique identifier for the document. The id may be represented by either @root or @root plus @extension, so long as the resulting id is globally unique.

CDA provides id, setId, versionNumber, and relatedDocument elements to support succession management (document versioning).

The id element identifies the CDA document instance (the electronic file). It is independent of the setId and versionNumber elements.

1. SHALL contain exactly one [1..1] id (CONF:86-18466).
   1. This id MAY contain zero or one [0..1] @root (CONF:86-18467).
   2. This id MAY contain zero or one [0..1] @extension (CONF:86-18468).
2. SHALL contain exactly one [1..1] code (CONF:86-18433).
   1. This code SHALL contain exactly one [1..1] @code="51897-7" Healthcare Associated Infection Report (CONF:86-18434).
   2. This code SHALL contain exactly one [1..1] @codeSystem (CodeSystem: LOINC urn:oid:2.16.840.1.113883.6.1) (CONF:86-27413).

The preferred title content for each report type is given with the constraints for each report type.

1. SHALL contain exactly one [1..1] title (CONF:86-18435).
2. SHALL contain exactly one [1..1] effectiveTime (CONF:86-18436).

CDA requires a confidentiality code that indicates the sensitivity of the document. All HAI submissions carry the same value of "normal". Note that this designation does not affect local policy on safeguarding confidentiality of patient-identifiable personal health information.

1. SHALL contain exactly one [1..1] confidentialityCode (CONF:86-18437).
   1. This confidentialityCode SHALL contain exactly one [1..1] @code="N" Normal (CodeSystem: HL7Confidentiality urn:oid:2.16.840.1.113883.5.25 STATIC) (CONF:86-18438).
2. SHALL contain exactly one [1..1] languageCode (CONF:86-18439).
   1. This languageCode SHALL contain exactly one [1..1] @code="en-US" (CONF:86-18440).
3. SHALL contain exactly one [1..1] setId (CONF:86-18441).
4. SHALL contain exactly one [1..1] versionNumber (CONF:86-18442).

CDA requires a recordTarget element that must contain a patientRole element. This is represented differently in single-person and population summary reports. See the templates for generic single-person and population summary reports for details of how to represent the patient or group subject.

1. SHALL contain at least one [1..\*] recordTarget (CONF:86-18472).

In a single-person report, the author may be software or may be a person in the role of infection control professional (ICP). In a population summary report, the author will be the software forming the message. The effect of the CDA Release 2.0 requirements is:  
An author element shall be present. The author element shall contain a time element that represents the time of authoring of the information, and an assignedAuthor element that represents the author of the information. The assignedAuthor element shall contain an id element.

When the report author is vendor software, it can record the Synthetic Data Set (SDS) Validation Id, or, if not participating in SDS, a software installation id. It can also record the vendor software name, the version and release of the software, and the vendor name. For further guidance, see the example at the end of this template.

1. SHALL contain at least one [1..\*] author (CONF:86-18473).

CDA requires that the document custodian be recorded. The NHSN is the custodian of NHSN HAI Reports.

1. SHALL contain exactly one [1..1] custodian (CONF:86-18443).
   1. This custodian SHALL contain exactly one [1..1] assignedCustodian (CONF:86-18444).
      1. This assignedCustodian SHALL contain exactly one [1..1] representedCustodianOrganization (CONF:86-18445).
         1. This representedCustodianOrganization SHALL contain exactly one [1..1] id (CONF:86-18446).
            1. This id SHALL contain exactly one [1..1] @root="2.16.840.1.114222.4.3.2.11" (CONF:86-18447).

CDA requires that a legalAuthenticator element be present if the document has been legally authenticated. Local policy may delegate the function of legal authentication to a device or system that generates the CDA document. In these cases, the legal authenticator must still be a person accepting responsibility for the document content, not the device or system. The effect of the CDA Release 2.0 requirements is:  
The legalAuthenticator element shall contain a time element that represents the time of authentication of the document, a signatureCode element where the value of @code is S, and an assignedEntity element that represents the authenticator of the document. The assignedEntity element shall contain an id element.  
HAI Reports are not signed reports and do not require a legalAuthenticator.

1. SHOULD contain zero or one [0..1] legalAuthenticator (CONF:86-18474).
2. MAY contain zero or more [0..\*] relatedDocument (CONF:86-18469).
   1. The relatedDocument, if present, SHALL contain exactly one [1..1] @typeCode="RPLC" replace (CodeSystem: HL7ActRelationshipType urn:oid:2.16.840.1.113883.5.1002 STATIC) (CONF:86-18470).
   2. The relatedDocument, if present, SHALL contain exactly one [1..1] parentDocument (CONF:86-28401).
      1. This parentDocument SHALL contain at least one [1..\*] id (CONF:86-28402).
         1. The value of id SHALL be populated with the ClinicalDocument/id of the document being replaced (CONF:86-28403).
   3. If versionNumber/@value is greater than 1, a relatedDocument element SHALL be present (CONF:86-18471).
3. SHALL contain exactly one [1..1] component (CONF:86-18448).
   1. This component SHALL contain exactly one [1..1] structuredBody (CONF:86-18449).
      1. This structuredBody SHALL contain at least one [1..\*] component (CONF:86-18475).
      2. The structuredBody element SHALL contain a component element for each section required by the particular report type. Additional sections may be present, but their content will not be processed by NHSN (CONF:86-18450).

Figure 23: Software Author Example

<author>

<!-- The time the document was authored -->

<time value="20080701" />

<assignedAuthor>

<!-- root=vendor OID; extension may be the Synthetic Data Set (SDS)

Validation ID assigned by NHSN AUR subject matter expert (SME);

if not participating in SDS, vendor may use a software ID -->

<id root="2.111.111.111.10008" extension="SDS validation ID" />

<assignedAuthoringDevice>

<!-- Optional-Vendor software name -->

<manufacturerModelName>vendor software name</manufacturerModelName>

<!-- Optional-version and release of the software-->

<softwareName>vendor software version</softwareName>

</assignedAuthoringDevice>

<!-- Optional-Vendor Name -->

<representedOrganization>

<name>vendor name</name>

</representedOrganization>

</assignedAuthor>

</author>

HAI Population Summary Report Generic Constraints

[ClinicalDocument: identifier urn:oid:2.16.840.1.113883.10.20.5.4.28 (open)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 1 - US Realm

A Population Summary Report records summary data for a group, such as the patients in a particular ward, during a specified period. This report type differs in several ways from the HAI single-person reports.

These report types are used to record many different data sets. The basic structure of the body templates for this report type are:  
• A Summary Data Section:  
o A Summary Encounter records the location to which the data pertain.  
o Various Summary Data Observations record data as code-value pairs.

A population-summary report must conform to the Healthcare Associated Infection Report above. In addition:  
• The patient identifier (required by CDA) is recorded with a nullFlavor.  
• A participant element records that the subject of the report is a group.  
• A second participant element records the reporting facility. (The in-facility unit identifier and type to which the data pertain are recorded in the Summary Encounter Section of the document body.)  
• In the documentationOf/serviceEvent element,  
o The effectiveTime element records the first and last days of the period reported.  
o The code element records the type of summary data reported. This corresponds to the NHSN form type.  
The data set being reported is identified by a code in the CDA header; for example, the cdcNHSN concept “1887-9” identifies the data set “Summary data reporting Antimicrobial Usage”. The codes for these data sets are listed in value set NHSNPopulationSummaryReportTypeCode (2.16.840.1.114222.4.11.3595).

Note that a few data sets are stratified. For example, the NICU (Neonatal Intensive Care Unit) data set is stratified by birthweight; the Antimicrobial Usage data set is stratified by antimicrobial and by route of administration. The stratifying factor is recorded as a CDA element in the Summary Encounter or Summary Data Observation. For example, in an Antimicrobial Use report, the antimicrobial information is represented as a participant. The requirements for each data set are provided in the relevant Summary Data Observation.

Most of the concepts reported are defined for the NHSN protocol and are not expected to see widespread external use: the codes for these concepts come from the NHSN code system.  
Key encounter data:  
• Facility identifier is required. This represents the reporting facility; the location to which the data pertain, such as a unit, is recorded with the data in the Summary Encounter.  
• A code identifying the data set is required.  
• The period reported is required.

Note: The section on “Template Ids in this Guide” includes a containment table showing all the entries within each report type.

Table 3: HAI Population Summary Report Generic Constraints Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| ClinicalDocument (identifier: urn:oid:2.16.840.1.113883.10.20.5.4.28) | | | | | |
| templateId | 1..1 | SHALL |  | [86-22431](#C_86-22431) |  |
| @root | 1..1 | SHALL |  | [86-22432](#C_86-22432) | 2.16.840.1.113883.10.20.5.4.28 |
| recordTarget | 1..1 | SHALL |  | [86-22433](#C_86-22433) |  |
| patientRole | 1..1 | SHALL |  | [86-22434](#C_86-22434) |  |
| id | 1..1 | SHALL |  | [86-22435](#C_86-22435) |  |
| @nullFlavor | 1..1 | SHALL |  | [86-22436](#C_86-22436) | NA |
| participant | 1..1 | SHALL |  | [86-22437](#C_86-22437) |  |
| @typeCode | 1..1 | SHALL |  | [86-22438](#C_86-22438) | urn:oid:2.16.840.1.113883.5.90 (HL7ParticipationType) = SBJ |
| @contextControlCode | 1..1 | SHALL | CS | [86-22439](#C_86-22439) | urn:oid:2.16.840.1.113883.5.1057 (HL7ContextControl) = OP |
| associatedEntity | 1..1 | SHALL |  | [86-22440](#C_86-22440) |  |
| @classCode | 1..1 | SHALL |  | [86-22441](#C_86-22441) | urn:oid:2.16.840.1.113883.5.41 (HL7EntityClass) = PRS |
| code | 1..1 | SHALL |  | [86-22442](#C_86-22442) |  |
| @code | 1..1 | SHALL |  | [86-22443](#C_86-22443) | urn:oid:2.16.840.1.113883.6.96 (SNOMED CT) = 389109008 |
| participant | 1..1 | SHALL |  | [86-22444](#C_86-22444) |  |
| @typeCode | 1..1 | SHALL |  | [86-22445](#C_86-22445) | urn:oid:2.16.840.1.113883.5.90 (HL7ParticipationType) = LOC |
| associatedEntity | 1..1 | SHALL |  | [86-22447](#C_86-22447) |  |
| @classCode | 1..1 | SHALL |  | [86-22448](#C_86-22448) | urn:oid:2.16.840.1.113883.5.110 (HL7RoleClass) = SDLOC |
| id | 1..1 | SHALL |  | [86-22449](#C_86-22449) |  |
| @root | 1..1 | SHALL |  | [86-22450](#C_86-22450) |  |
| documentationOf | 1..1 | SHALL |  | [86-22451](#C_86-22451) |  |
| serviceEvent | 1..1 | SHALL |  | [86-22452](#C_86-22452) |  |
| @classCode | 1..1 | SHALL |  | [86-22453](#C_86-22453) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = CASE |
| code | 1..1 | SHALL |  | [86-22454](#C_86-22454) | urn:oid:2.16.840.1.114222.4.11.3595 (NHSNPopulationSummaryReportTypeCode) |
| effectiveTime | 1..1 | SHALL |  | [86-22456](#C_86-22456) |  |
| low | 1..1 | SHALL |  | [86-22457](#C_86-22457) |  |
| high | 1..1 | SHALL |  | [86-22458](#C_86-22458) |  |

1. Conforms to [Healthcare Associated Infection Report](#D_Healthcare_Associated_Infection_Repor) template (identifier: urn:oid:2.16.840.1.113883.10.20.5.4.25).
2. SHALL contain exactly one [1..1] templateId (CONF:86-22431) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.4.28" (CONF:86-22432).
3. SHALL contain exactly one [1..1] recordTarget (CONF:86-22433).
   1. This recordTarget SHALL contain exactly one [1..1] patientRole (CONF:86-22434).
      1. This patientRole SHALL contain exactly one [1..1] id (CONF:86-22435).
         1. This id SHALL contain exactly one [1..1] @nullFlavor="NA" not applicable (CONF:86-22436).
4. SHALL contain exactly one [1..1] participant (CONF:86-22437) such that it
   1. SHALL contain exactly one [1..1] @typeCode="SBJ" Subject (CodeSystem: HL7ParticipationType urn:oid:2.16.840.1.113883.5.90 STATIC) (CONF:86-22438).
   2. SHALL contain exactly one [1..1] @contextControlCode="OP" (CodeSystem: HL7ContextControl urn:oid:2.16.840.1.113883.5.1057 STATIC) (CONF:86-22439).
   3. SHALL contain exactly one [1..1] associatedEntity (CONF:86-22440).
      1. This associatedEntity SHALL contain exactly one [1..1] @classCode="PRS" Person (CodeSystem: HL7EntityClass urn:oid:2.16.840.1.113883.5.41 STATIC) (CONF:86-22441).
      2. This associatedEntity SHALL contain exactly one [1..1] code (CONF:86-22442).
         1. This code SHALL contain exactly one [1..1] @code="389109008" Group (CodeSystem: SNOMED CT urn:oid:2.16.840.1.113883.6.96 STATIC) (CONF:86-22443).
5. SHALL contain exactly one [1..1] participant (CONF:86-22444) such that it
   1. SHALL contain exactly one [1..1] @typeCode="LOC" Location (CodeSystem: HL7ParticipationType urn:oid:2.16.840.1.113883.5.90 STATIC) (CONF:86-22445).
   2. SHALL contain exactly one [1..1] associatedEntity (CONF:86-22447).
      1. This associatedEntity SHALL contain exactly one [1..1] @classCode="SDLOC" Service delivery location (CodeSystem: HL7RoleClass urn:oid:2.16.840.1.113883.5.110 STATIC) (CONF:86-22448).
      2. This associatedEntity SHALL contain exactly one [1..1] id (CONF:86-22449).

The value of @root must be the NHSN assigned Facility OID.

* + - 1. This id SHALL contain exactly one [1..1] @root (CONF:86-22450).

1. SHALL contain exactly one [1..1] documentationOf (CONF:86-22451).
   1. This documentationOf SHALL contain exactly one [1..1] serviceEvent (CONF:86-22452).
      1. This serviceEvent SHALL contain exactly one [1..1] @classCode="CASE" (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6 STATIC) (CONF:86-22453).
      2. This serviceEvent SHALL contain exactly one [1..1] code, which SHALL be selected from ValueSet [NHSNPopulationSummaryReportTypeCode](#NHSNPopulationSummaryReportTypeCode) urn:oid:2.16.840.1.114222.4.11.3595 DYNAMIC (CONF:86-22454).
      3. This serviceEvent SHALL contain exactly one [1..1] effectiveTime (CONF:86-22456).
         1. This effectiveTime SHALL contain exactly one [1..1] low (CONF:86-22457).
         2. This effectiveTime SHALL contain exactly one [1..1] high (CONF:86-22458).
2. The author SHALL represent the software forming the message (CONF:86-22459).

Table 4: NHSNPopulationSummaryReportTypeCode

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSNPopulationSummaryReportTypeCode urn:oid:2.16.840.1.114222.4.11.3595  (Clinical Focus: NHSN surveillance reporting: This value set contains codes describing the type of population summary report.),(Data Element Scope: A code describing the population category associated with the data being reported.),(Inclusion Criteria: ),(Exclusion Criteria: )  This value set was imported on 9/16/2020 with a version of Latest.  Value Set Source: <https://vsac.nlm.nih.gov/valueset/2.16.840.1.114222.4.11.3595/expansion> | | | |
| Code | Code System | Code System OID | Print Name |
| 1657-6 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting outpatient procedure component events at a facility |
| 1879-6 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting catheter and ventilator use in a ICU/other |
| 1880-4 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting catheter and ventilator use in a SCA |
| 1881-2 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting catheter and ventilator use in a NICU |
| 1884-6 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting active surveillance testing (AST) |
| 1887-9 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting antimicrobial usage |
| 1891-1 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting MDRO and CDI LabID Event for LTCF |
| 2316-8 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting vascular access types for chronic hemodialysis patients |
| 2410-9 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Summary data reporting antimicrobial resistance patterns at a facility |
| 2543-7 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Hemovigilance module - monthly reporting denominator |
| ... | | | |

Hemovigilance (HV) Summary Report (V2)

[ClinicalDocument: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.49:2016-08-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1 - US Realm

Table 5: Hemovigilance (HV) Summary Report (V2) Contexts

| Contained By: | Contains: |
| --- | --- |
|  | [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) (required) |

Note: The section on “Template Ids in this Guide” includes a containment table showing all the entries within each report type.

The required title for the CDA document is the “Hemovigilance Module - Monthly Reporting Denominator”.

The HV Summary Report records monthly summary data for a facility.

Table 6: Hemovigilance (HV) Summary Report (V2) Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| ClinicalDocument (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.49:2016-08-01) | | | | | |
| templateId | 1..1 | SHALL |  | [3247-30738](#C_3247-30738) |  |
| @root | 1..1 | SHALL |  | [3247-30608](#C_3247-30608) | 2.16.840.1.113883.10.20.5.7.3.1.1 |
| templateId | 1..1 | SHALL |  | [3247-30606](#C_3247-30606) |  |
| @root | 1..1 | SHALL |  | [3247-30611](#C_3247-30611) | 2.16.840.1.113883.10.20.5.49 |
| @extension | 1..1 | SHALL |  | [3247-30612](#C_3247-30612) | 2016-08-01 |
| title | 1..1 | SHALL |  | [3247-30613](#C_3247-30613) |  |
| documentationOf | 1..1 | SHALL |  | [3247-30600](#C_3247-30600) |  |
| serviceEvent | 1..1 | SHALL |  | [3247-30739](#C_3247-30739) |  |
| code | 1..1 | SHALL |  | [3247-30740](#C_3247-30740) |  |
| @code | 1..1 | SHALL |  | [3247-30609](#C_3247-30609) | 2543-7 |
| @codeSystem | 1..1 | SHALL |  | [3247-30610](#C_3247-30610) | urn:oid:2.16.840.1.113883.6.277 (cdcNHSN) = 2.16.840.1.113883.6.277 |
| component | 1..1 | SHALL |  | [3247-30741](#C_3247-30741) |  |
| structuredBody | 1..1 | SHALL |  | [3247-30604](#C_3247-30604) |  |
| component | 1..1 | SHALL |  | [3247-30605](#C_3247-30605) |  |
| section | 1..1 | SHALL |  | [3247-30607](#C_3247-30607) | [Summary Data Section (HV) (V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.5.57:2016-08-01](#S_Summary_Data_Section_HV_V2) |

1. Conforms to [HAI Population Summary Report Generic Constraints](#D_HAI_Population_Summary_Report_Generic) template (identifier: urn:oid:2.16.840.1.113883.10.20.5.4.28).

This template id represents the IG in which this template is published.

1. SHALL contain exactly one [1..1] templateId (CONF:3247-30738) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.7.3.1.1" (CONF:3247-30608).
2. SHALL contain exactly one [1..1] templateId (CONF:3247-30606) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.49" (CONF:3247-30611).
   2. SHALL contain exactly one [1..1] @extension="2016-08-01" (CONF:3247-30612).

Preferred document title: "Hemovigilance Module - Monthly Reporting Denominator"

1. SHALL contain exactly one [1..1] title (CONF:3247-30613).
2. SHALL contain exactly one [1..1] documentationOf (CONF:3247-30600).
   1. This documentationOf SHALL contain exactly one [1..1] serviceEvent (CONF:3247-30739).
      1. This serviceEvent SHALL contain exactly one [1..1] code (CONF:3247-30740).
         1. This code SHALL contain exactly one [1..1] @code="2543-7" Hemovigilance Module - Monthly Reporting Denominator (CONF:3247-30609).
         2. This code SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.6.277" (CodeSystem: cdcNHSN urn:oid:2.16.840.1.113883.6.277) (CONF:3247-30610).
3. SHALL contain exactly one [1..1] component (CONF:3247-30741).
   1. This component SHALL contain exactly one [1..1] structuredBody (CONF:3247-30604).
      1. This structuredBody SHALL contain exactly one [1..1] component (CONF:3247-30605).
         1. This component SHALL contain exactly one [1..1] [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.5.57:2016-08-01) (CONF:3247-30607).

# Section-Level Templates

HAI Section Generic Constraints

[section: identifier urn:oid:2.16.840.1.113883.10.20.5.4.26 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 1 - US Realm

This template records the constraints that apply to all sections specified in the NHSN HAI Implementation Guide.

Table 7: HAI Section Generic Constraints Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| section (identifier: urn:oid:2.16.840.1.113883.10.20.5.4.26) | | | | | |
| templateId | 1..1 | SHALL |  | [86-21958](#C_86-21958) |  |
| @root | 1..1 | SHALL |  | [86-21959](#C_86-21959) | 2.16.840.1.113883.10.20.5.4.26 |
| code | 1..1 | SHALL |  | [86-21953](#C_86-21953) |  |
| @code | 1..1 | SHALL |  | [86-21954](#C_86-21954) | urn:oid:2.16.840.1.113883.6.1 (LOINC) |
| title | 1..1 | SHALL |  | [86-21955](#C_86-21955) |  |
| text | 1..1 | SHALL |  | [86-21956](#C_86-21956) |  |
| entry | 1..\* | SHALL |  | [86-21957](#C_86-21957) |  |

1. SHALL contain exactly one [1..1] templateId (CONF:86-21958) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.4.26" (CONF:86-21959).
2. SHALL contain exactly one [1..1] code (CONF:86-21953).
   1. This code SHALL contain exactly one [1..1] @code (CodeSystem: LOINC urn:oid:2.16.840.1.113883.6.1 STATIC) (CONF:86-21954).
3. SHALL contain exactly one [1..1] title (CONF:86-21955).
4. SHALL contain exactly one [1..1] text (CONF:86-21956).
5. SHALL contain at least one [1..\*] entry (CONF:86-21957).

Summary Data Section (HV) (V2)

[section: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.5.57:2016-08-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1 - US Realm

Table 8: Summary Data Section (HV) (V2) Contexts

| Contained By: | Contains: |
| --- | --- |
| [Hemovigilance (HV) Summary Report (V2)](#D_Hemovigilance_HV_Summary_Report_V2) (required) | [No Hemovigilance Adverse Reactions Reported This Month Observation](#E_No_Hemovigilance_Adverse_Reactions_Re) (required)  [No Hemovigilance Incidents Reported This Month Observation](#E_No_Hemovigilance_Incidents_Reported_T) (required)  [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) (required) |

The Summary Data Section is used in a population summary report. The specific counts to be reported in the Summary Data Section vary by report topic, but the section itself conveys the same kind of information wherever used; therefore, the section is represented by the same LOINC section code whatever the data reported.

The Summary Data Section (HV) extends its generic equivalent but is specific to the HAI Hemovigilance (HV) Summary Report.

Table 9: Summary Data Section (HV) (V2) Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| section (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.5.57:2016-08-01) | | | | | |
| templateId | 1..1 | SHALL |  | [3247-30615](#C_3247-30615) |  |
| @root | 1..1 | SHALL |  | [3247-30619](#C_3247-30619) | 2.16.840.1.113883.10.20.5.5.57 |
| @extension | 1..1 | SHALL |  | [3247-30620](#C_3247-30620) | 2016-08-01 |
| code | 1..1 | SHALL |  | [3247-30616](#C_3247-30616) |  |
| @code | 1..1 | SHALL |  | [3247-30621](#C_3247-30621) | 51900-9 |
| @codeSystem | 1..1 | SHALL |  | [3247-30622](#C_3247-30622) | urn:oid:2.16.840.1.113883.6.1 (LOINC) = 2.16.840.1.113883.6.1 |
| entry | 1..1 | SHALL |  | [3247-30614](#C_3247-30614) |  |
| observation | 1..1 | SHALL |  | [3247-30685](#C_3247-30685) | [No Hemovigilance Adverse Reactions Reported This Month Observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.232:2015-10-01](#E_No_Hemovigilance_Adverse_Reactions_Re) |
| entry | 1..\* | SHALL |  | [3247-30617](#C_3247-30617) |  |
| observation | 1..1 | SHALL |  | [3247-30686](#C_3247-30686) | [No Hemovigilance Incidents Reported This Month Observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.233:2015-10-01](#E_No_Hemovigilance_Incidents_Reported_T) |
| entry | 1..\* | SHALL |  | [3247-30736](#C_3247-30736) |  |
| encounter | 1..1 | SHALL |  | [3247-30737](#C_3247-30737) | [Summary Encounter (HV) (V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.234:2016-08-01](#E_Summary_Encounter_HV_V2) |

1. Conforms to [HAI Section Generic Constraints](#S_HAI_Section_Generic_Constraints) template (identifier: urn:oid:2.16.840.1.113883.10.20.5.4.26).
2. SHALL contain exactly one [1..1] templateId (CONF:3247-30615) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.5.57" (CONF:3247-30619).
   2. SHALL contain exactly one [1..1] @extension="2016-08-01" (CONF:3247-30620).
3. SHALL contain exactly one [1..1] code (CONF:3247-30616).
   1. This code SHALL contain exactly one [1..1] @code="51900-9" Summary Data Section (CONF:3247-30621).
   2. This code SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.6.1" (CodeSystem: LOINC urn:oid:2.16.840.1.113883.6.1) (CONF:3247-30622).
4. SHALL contain exactly one [1..1] entry (CONF:3247-30614) such that it
   1. SHALL contain exactly one [1..1] [No Hemovigilance Adverse Reactions Reported This Month Observation](#E_No_Hemovigilance_Adverse_Reactions_Re) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.232:2015-10-01) (CONF:3247-30685).
5. SHALL contain at least one [1..\*] entry (CONF:3247-30617) such that it
   1. SHALL contain exactly one [1..1] [No Hemovigilance Incidents Reported This Month Observation](#E_No_Hemovigilance_Incidents_Reported_T) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.233:2015-10-01) (CONF:3247-30686).
6. SHALL contain at least one [1..\*] entry (CONF:3247-30736) such that it
   1. SHALL contain exactly one [1..1] [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.234:2016-08-01) (CONF:3247-30737).

Figure 24: Summary Data Section (HV) (V2) Example

<section>

<!-- [HAI R1] HAI Section Generic Constraints -->

<templateId root="2.16.840.1.113883.10.20.5.4.26" />

<!-- [HAI R3D1.1] Summary Data Section (HV) (V2) -->

<templateId root="2.16.840.1.113883.10.20.5.5.57"

extension="2016-08-01" />

<code codeSystem="2.16.840.1.113883.6.1"

codeSystemName="LOINC" code="51900-9"

displayName="Summary Data Section" />

<title>Summary Data</title>

<text>...</text>

<entry typeCode="DRIV">

<!-- No Adverse Reactions Reported This Month Observation -->

<observation classCode="OBS" moodCode="EVN"

negationInd="false">

<!-- [HAI R3D1] No Adverse Reactions Reported This Month Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.232"

extension="2015-10-01"

/>

...

</observation>

</entry>

<entry typeCode="DRIV">

<!-- No Incidents Reported This Month Observation -->

<observation classCode="OBS" moodCode="EVN"

negationInd="true">

<!-- [HAI R3D1] No Incidents Reported This Month Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.233"

extension="2015-10-01"

/>

...

</observation>

</entry>

<entry typeCode="DRIV">

<encounter classCode="ENC" moodCode="EVN">

<!-- [HAI R3D1.1] Summary Encounter (HV) (V2)-->

<templateId root="2.16.840.1.113883.10.20.5.6.234"

extension="2016-08-01" />

...

</encounter>

</entry>

</section>

# Entry-Level Templates

Blood Product Usage Summary Observation (V2)

[observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.237:2016-08-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1 - US Realm

Table 10: Blood Product Usage Summary Observation (V2) Contexts

| Contained By: | Contains: |
| --- | --- |
| [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) (required) | [ISBT Product Code Summary Observation (V2)](#E_ISBT_Product_Code_Summary_ObsV2) (optional) |

This template represents the number of units transfused, aliquots transfused, or total discards for each type of blood product.

If the value = 0 or type of product is one of the following, there SHALL NOT be a contained observation:

* Red Blood Cells/Whole Blood Derived/Total (3401-7, 3402-5, 3470-2)
* Red Blood Cells/Apheresis/Total (3409-0, 3410-8, 3477-7)
* Platelets/Whole Blood Derived/Total (3417-3, 3484-3)
* Platelets/Apheresis/Total (3421-5, 3422-3, 3490-0)
* Red Blood Cells/Whole Blood Derived/S-303 and Riboflavin Treated/Total (3544-4, 3545-1, 3546-9)
* Red Blood Cells/Apheresis/S-303 and Riboflavin Treated/Total (3553-5, 3554-3, 3555-0)
* Platelets/Whole Blood Derived/Psoralen and Riboflavin Treated/Total (3502-2, 3504-8)
* Platelets/Apheresis/Psoralen and Riboflavin Treated/Total (3511-3, 3512-1, 3513-9)
* Plasma/Whole Blood Derived/Psoralen and Riboflavin Treated/Total (3520-4, 3521-2, 3522-0)
* Plasma/Apheresis/Psoralen and Riboflavin Treated/Total (3529-5, 3530-3, 3531-1)
* Cryoprecipitate/Psoralen and Riboflavin Treated/Total (3562-6, 3563-4)  
  If the value is > 0 and the type of product is not one of those listed above, then each specific subcategory product that is > 0 SHALL be listed in a separate contained ISBT Product Code Summary Observation.

Table 11: Blood Product Usage Summary Observation (V2) Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.237:2016-08-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [3247-30705](#C_3247-30705) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | [3247-30706](#C_3247-30706) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| templateId | 1..1 | SHALL |  | [3247-30701](#C_3247-30701) |  |
| @root | 1..1 | SHALL |  | [3247-30707](#C_3247-30707) | 2.16.840.1.113883.10.20.5.6.237 |
| @extension | 1..1 | SHALL |  | [3247-30714](#C_3247-30714) | 2016-08-01 |
| code | 1..1 | SHALL |  | [3247-30702](#C_3247-30702) |  |
| @code | 1..1 | SHALL |  | [3247-30715](#C_3247-30715) | urn:oid:2.16.840.1.114222.4.11.7353 (NHSNSummaryBloodProductUsage) |
| statusCode | 1..1 | SHALL |  | [3247-30703](#C_3247-30703) |  |
| @code | 1..1 | SHALL |  | [3247-30713](#C_3247-30713) | urn:oid:2.16.840.1.113883.5.14 (HL7ActStatus) = completed |
| value | 1..1 | SHALL | INT | [3247-30704](#C_3247-30704) |  |
| entryRelationship | 0..\* | SHOULD |  | [3247-30728](#C_3247-30728) |  |
| observation | 1..1 | SHALL |  | [3247-30729](#C_3247-30729) | [ISBT Product Code Summary Observation (V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01](#E_ISBT_Product_Code_Summary_ObsV2) |

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6) (CONF:3247-30705).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001) (CONF:3247-30706).
3. SHALL contain exactly one [1..1] templateId (CONF:3247-30701) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.237" (CONF:3247-30707).
   2. SHALL contain exactly one [1..1] @extension="2016-08-01" (CONF:3247-30714).
4. SHALL contain exactly one [1..1] code (CONF:3247-30702).
   1. This code SHALL contain exactly one [1..1] @code, which SHALL be selected from ValueSet [NHSNSummaryBloodProductUsage](#NHSNSummaryBloodProductUsage) urn:oid:2.16.840.1.114222.4.11.7353 DYNAMIC (CONF:3247-30715).
5. SHALL contain exactly one [1..1] statusCode (CONF:3247-30703).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: HL7ActStatus urn:oid:2.16.840.1.113883.5.14) (CONF:3247-30713).
6. SHALL contain exactly one [1..1] value with @xsi:type="INT" (CONF:3247-30704).
7. SHOULD contain zero or more [0..\*] entryRelationship (CONF:3247-30728).
   1. The entryRelationship, if present, SHALL contain exactly one [1..1] [ISBT Product Code Summary Observation (V2)](#E_ISBT_Product_Code_Summary_ObsV2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01) (CONF:3247-30729).
8. If the value = 0 or type of product is one of the following, there SHALL NOT be a contained observation:

Table 12: NHSNSummaryBloodProductUsage

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSNSummaryBloodProductUsage urn:oid:2.16.840.1.114222.4.11.7353  (Clinical Focus: NHSN surveillance reporting: monthly reporting denominators for hemovigilance),(Data Element Scope: Code identifying the type of observation.),(Inclusion Criteria: ),(Exclusion Criteria: )  This value set was imported on 10/14/2020 with a version of Latest.  Value Set Source: <https://vsac.nlm.nih.gov/valueset/2.16.840.1.114222.4.11.7353/expansion> | | | |
| Code | Code System | Code System OID | Print Name |
| 3401-7 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Total number of units transfused: Red Blood Cells: Whole blood-derived |
| 3402-5 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Total number of aliquots transfused: Red Blood Cells: Whole blood-derived |
| ... | | | |

Figure 25: Blood Product Usage Summary Observation (V2) Example

<observation classCode="OBS" moodCode="EVN">

<!-- [HAI R3D1.1] Blood Product Usage Summary Observation (V2) -->

<templateId root="2.16.840.1.113883.10.20.5.6.237" extension="2016-08-01" />

<code codeSystem="2.16.840.1.113883.6.277"

codeSystemName="cdcNHSN"

code="3467-8"

displayName="Total number of units transfused - Whole blood" />

<statusCode code="completed" />

<value xsi:type="INT" value="100" />

<!--

If the value = 0 or type of product is one of the following,

there SHALL NOT be a contained observation:

Red Blood Cells/Whole Blood Derived/Total (3401-7, 3402-5, 3470-2)

Red Blood Cells/Apheresis/Total (3409-0, 3410-8, 3477-7)

Platelets/Whole Blood Derived/Total (3417-3, 3484-3)

Platelets/Apheresis/Total (3421-5, 3422-3, 3490-0)

Red Blood Cells/Whole Blood Derived/S-303 and Riboflavin Treated/Total (3544-4, 3545-1, 3546-9)

Red Blood Cells/Apheresis/S-303 and Riboflavin Treated/Total (3553-5, 3554-3, 3555-0)

Platelets/Whole Blood Derived/Psoralen and Riboflavin Treated/Total (3502-2, 3504-8)

Platelets/Apheresis/Psoralen and Riboflavin Treated/Total (3511-3, 3512-1, 3513-9)

Plasma/Whole Blood Derived/Psoralen and Riboflavin Treated/Total (3520-4, 3521-2, 3522-0)

Plasma/Apheresis/Psoralen and Riboflavin Treated/Total (3529-5, 3530-3, 3531-1)

Cryoprecipitate/Psoralen and Riboflavin Treated/Total (3562-6, 3563-4)

If the value is > 0 and the type of product is not one of those listed above,

then each specific subcategory product that is > 0 SHALL be listed in a

separate contained ISBT Product Code Summary Observation.

-->

<entryRelationship typeCode="COMP">

<observation classCode="OBS" moodCode="EVN">

<!-- ISBT Product Code Summary Observation (V2) -->

<templateId root="2.16.840.1.113883.10.20.5.6.238" extension="2016-08-01" />

..

</observation>

</entryRelationship>

...

</observation>

Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2)

[observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.236:2016-08-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1 - US Realm

Table 13: Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) Contexts

| Contained By: | Contains: |
| --- | --- |
| [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) (required) |  |

This clinical statement represents whether or not the facility transfuses blood products treated with pathogen reduction technology.

If the facility does transfuse blood products treated with pathogen reduction technology, set the value of @negationInd to false. If the facility does not transfuse blood products treated with pathogen reduction technology, set the value of @negationInd to true.

Table 14: Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.236:2016-08-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [3247-30698](#C_3247-30698) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | [3247-30699](#C_3247-30699) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| @negationInd | 1..1 | SHALL |  | [3247-30700](#C_3247-30700) |  |
| templateId | 1..1 | SHALL |  | [3247-30690](#C_3247-30690) |  |
| @root | 1..1 | SHALL |  | [3247-30696](#C_3247-30696) | 2.16.840.1.113883.10.20.5.6.236 |
| @extension | 1..1 | SHALL |  | [3247-30697](#C_3247-30697) | 2016-08-01 |
| code | 1..1 | SHALL |  | [3247-30687](#C_3247-30687) |  |
| @code | 1..1 | SHALL | CS | [3247-30691](#C_3247-30691) | ASSERTION |
| @codeSystem | 1..1 | SHALL |  | [3247-30692](#C_3247-30692) | urn:oid:2.16.840.1.113883.5.4 (HL7ActCode) = 2.16.840.1.113883.5.4 |
| statusCode | 1..1 | SHALL |  | [3247-30688](#C_3247-30688) |  |
| @code | 1..1 | SHALL |  | [3247-30693](#C_3247-30693) | urn:oid:2.16.840.1.113883.5.14 (HL7ActStatus) = completed |
| value | 1..1 | SHALL | CD | [3247-30689](#C_3247-30689) |  |
| @code | 1..1 | SHALL |  | [3247-30694](#C_3247-30694) | 3542-8 |
| @codeSystem | 1..1 | SHALL |  | [3247-30695](#C_3247-30695) | urn:oid:2.16.840.1.113883.6.277 (cdcNHSN) = 2.16.840.1.113883.6.277 |

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6 STATIC) (CONF:3247-30698).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001 STATIC) (CONF:3247-30699).

If the facility does transfuse blood products treated with pathogen reduction technology, set the value of @negationInd to false. If the facility does not transfuse blood products treated with pathogen reduction technology, set the value of @negationInd to true.

1. SHALL contain exactly one [1..1] @negationInd (CONF:3247-30700).
2. SHALL contain exactly one [1..1] templateId (CONF:3247-30690) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.236" (CONF:3247-30696).
   2. SHALL contain exactly one [1..1] @extension="2016-08-01" (CONF:3247-30697).
3. SHALL contain exactly one [1..1] code (CONF:3247-30687).
   1. This code SHALL contain exactly one [1..1] @code="ASSERTION" Assertion (CONF:3247-30691).
   2. This code SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.5.4" (CodeSystem: HL7ActCode urn:oid:2.16.840.1.113883.5.4) (CONF:3247-30692).
4. SHALL contain exactly one [1..1] statusCode (CONF:3247-30688).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: HL7ActStatus urn:oid:2.16.840.1.113883.5.14 STATIC) (CONF:3247-30693).
5. SHALL contain exactly one [1..1] value with @xsi:type="CD" (CONF:3247-30689).
   1. This value SHALL contain exactly one [1..1] @code="3542-8" Facility transfuses blood products treated with pathogen reduction technology (CONF:3247-30694).
   2. This value SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.6.277" (CodeSystem: cdcNHSN urn:oid:2.16.840.1.113883.6.277) (CONF:3247-30695).

Figure 26: Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) Example

<!-- Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation -->

<!-- If the facility does transfuse blood products treated with pathogen reduction technology,

set the value of @negationInd to false.

If the facility does not transfuse blood products treated with pathogen reduction technology,

set the value of @negationInd to true. -->

<!-- The facility does transfuse blood products treated with pathogen reduction technology

so negationInd='false' -->

<observation classCode="OBS" moodCode="EVN" negationInd="false">

<!-- [HAI R3D1.1] Facility Transfuses Blood Products Treated with

Pathogen Reduction Technology Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.236" extension="2016-08-01" />

<code code="ASSERTION" codeSystem="2.16.840.1.113883.5.4" />

<statusCode code="completed" />

<value xsi:type="CD"

codeSystem="2.16.840.1.113883.6.277"

codeSystemName="cdcNHSN"

code="3542-8"

displayName="Facility transfuses blood products treated with pathogen reduction technology" />

</observation>

ISBT Product Code Summary Observation (V2)

[observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1 - US Realm

Table 15: ISBT Product Code Summary Observation (V2) Contexts

| Contained By: | Contains: |
| --- | --- |
| [Blood Product Usage Summary Observation (V2)](#E_Blood_Product_Usage_Summary_Obs_V2) (optional)  [Pathogen Reduced Apheresis Platelet Usage Summary Observation](#E_Pathogen_Reduced_Apheresis_Platelet_U) (optional) |  |

This observation represents the number of units transfused, aliquots transfused, or total discards for each group of blood product split out by type, collection method, and modification or pathogen-reduction methodology, broken down by ISBT (International Society for Blood Transfusion) Product Code.

Table 16: ISBT Product Code Summary Observation (V2) Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [3247-30724](#C_3247-30724) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | [3247-30725](#C_3247-30725) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| templateId | 1..1 | SHALL |  | [3247-30716](#C_3247-30716) |  |
| @root | 1..1 | SHALL |  | [3247-30719](#C_3247-30719) | 2.16.840.1.113883.10.20.5.6.238 |
| @extension | 1..1 | SHALL |  | [3247-30720](#C_3247-30720) | 2016-08-01 |
| code | 1..1 | SHALL |  | [3247-30717](#C_3247-30717) |  |
| statusCode | 1..1 | SHALL |  | [3247-30718](#C_3247-30718) |  |
| @code | 1..1 | SHALL |  | [3247-30722](#C_3247-30722) | urn:oid:2.16.840.1.113883.5.14 (HL7ActStatus) = completed |
| value | 1..1 | SHALL | INT | [3247-30723](#C_3247-30723) |  |

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6) (CONF:3247-30724).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001) (CONF:3247-30725).
3. SHALL contain exactly one [1..1] templateId (CONF:3247-30716) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.238" (CONF:3247-30719).
   2. SHALL contain exactly one [1..1] @extension="2016-08-01" (CONF:3247-30720).

The value sets bound to the code element can be sourced from NHSN.

1. SHALL contain exactly one [1..1] code (CONF:3247-30717).
   1. If the product specified in the containing Blood Product Usage Summary Observation is Whole Blood (3467-8, 3468-6, 3469-4), then valueSet NHSN Whole Blood Total (urn:oid:2.16.840.1.114222.4.11.7292) SHALL be used (CONF:3247-30726).
   2. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Whole Blood Derived/Not irradiated or Leukocyte Reduced (3471-0, 3472-8, 3473-6), then valueSet NHSN Red Blood Cells/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7294) SHALL be used (CONF:3247-30727).
   3. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Whole Blood Derived/Irradiated (3403-3, 3404-1, 3474-4), then valueSet NHSN Red Blood Cells/Whole Blood Derived/Irradiated (urn:oid:2.16.840.1.114222.4.11.7295) SHALL be used (CONF:3247-30765).
   4. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Whole Blood Derived/Irradiated and Leukocyte Reduced (3407-4, 3408-2, 3476-9), then valueSet NHSN Red Blood Cells/Whole Blood Derived/Irradiated and Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7297) SHALL be used (CONF:3247-30766).
   5. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Apheresis/Not Irradiated or Leukocyte Reduced (3478-5, 3479-3, 3480-1), then valueSet NHSN Red Blood Cells/Apheresis/Not Irradiated or Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7299) SHALL be used (CONF:3247-30768).
   6. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Apheresis/Irradiated (3411-6, 3412-4, 3481-9), then valueSet NHSN Red Blood Cells/Apheresis/Irradiated (urn:oid:2.16.840.1.114222.4.11.7300) SHALL be used (CONF:3247-30742).
   7. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Apheresis/Leukocyte Reduced (3413-2, 3414-0, 3482-7), then valueSet NHSN Red Blood Cells/Apheresis/Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7301) SHALL be used (CONF:3247-30743).
   8. If the product specified in the containing Blood Product Usage Summary Observation is Plasma/Apheresis/Riboflavin-Treated (3535-2, 3536-0, 3537-8), then valueSet NHSN Plasma/Apheresis/Riboflavin-Treated (urn:oid:2.16.840.1.114222.4.11.7327) SHALL be used (CONF:3247-30744).
   9. If the product specified in the containing Blood Product Usage Summary Observation is Plasma/Apheresis/Psoralen-Treated (3532-9, 3533-7, 3534-5), then valueSet NHSN Plasma/Apheresis/Psoralen-Treated (urn:oid:2.16.840.1.114222.4.11.7326) SHALL be used (CONF:3247-30745).
   10. If the product specified in the containing Blood Product Usage Summary Observation is Plasma/Whole Blood Derived/Riboflavin-Treated (3526-1, 3527-9, 3528-7), then valueSet NHSN Plasma/Whole Blood Derived/Riboflavin-Treated (urn:oid:2.16.840.1.114222.4.11.7324) SHALL be used (CONF:3247-30746).
   11. If the product specified in the containing Blood Product Usage Summary Observation is Plasma/Whole Blood Derived/Psoralen-Treated (3523-8, 3524-6, 3525-3), then valueSet NHSN Plasma/Whole Blood Derived/Psoralen-Treated (urn:oid:2.16.840.1.114222.4.11.7323) SHALL be used (CONF:3247-30747).
   12. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Riboflavin-Treated (3517-0, 3518-8, 3519-6 ), then valueSet NHSN Platelets/Apheresis/Riboflavin-Treated (urn:oid:2.16.840.1.114222.4.11.7321) SHALL be used (CONF:3247-30748).
   13. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Psoralen-Treated (3514-7, 3515-4, 3516-2), then valueSet NHSN Platelets/Apheresis/Psoralen-Treated (urn:oid:2.16.840.1.114222.4.11.7320) SHALL be used (CONF:3247-30749).
   14. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Whole Blood Derived/Riboflavin-Treated (3517-0, 3518-8), then valueSet NHSN Platelets/Whole Blood Derived/Riboflavin-Treated (urn:oid:2.16.840.1.114222.4.11.7318) SHALL be used (CONF:3247-30750).
   15. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Whole Blood Derived/Psoralen-Treated (3505-5, 3507-1), then valueSet NHSN Platelets/Whole Blood Derived/Psoralen-Treated (urn:oid:2.16.840.1.114222.4.11.7317) SHALL be used (CONF:3247-30751).
   16. If the product specified in the containing Blood Product Usage Summary Observation is Cryoprecipitate (3562-6, 3563-4), then valueSet NHSN Cryoprecipitate (urn:oid:2.16.840.1.114222.4.11.7315) SHALL be used (CONF:3247-30752).
   17. If the product specified in the containing Blood Product Usage Summary Observation is Plasma/Apheresis/Total (3529-5, 3530-3, 3531-1), then valueSet NHSN Plasma/Apheresis/Total (urn:oid:2.16.840.1.114222.4.11.7314) SHALL be used (CONF:3247-30753).
   18. If the product specified in the containing Blood Product Usage Summary Observation is Plasma/Whole Blood Derived/Total (3520-4, 3521-2, 3522-0), then valueSet NHSN Plasma/Whole Blood Derived/Total (urn:oid:2.16.840.1.114222.4.11.7313) SHALL be used (CONF:3247-30754).
   19. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Irradiated or Leukocyte Reduced (3427-2, 3428-0, 3496-7), then valueSet NHSN Platelets/Apheresis/Irradiated or Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7312) SHALL be used (CONF:3247-30755).
   20. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Leukocyte Reduced (3425-6, 3426-4, 3495-9), then valueSet NHSN Platelets/Apheresis/Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7311) SHALL be used (CONF:3247-30756).
   21. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Irradiated (3423-1, 3424-9, 3494-2), then valueSet NHSN Platelets/Apheresis/Irradiated (urn:oid:2.16.840.1.114222.4.11.7310) SHALL be used (CONF:3247-30757).
   22. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Not Irradiated or Leukocyte Reduced (3491-8, 3492-6, 3493-4), then valueSet NHSN Platelets/Apheresis/Not Irradiated or Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7309) SHALL be used (CONF:3247-30758).
   23. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Whole Blood Derived/Irradiated and Leukocyte Reduced (3420-7, 3489-2), then valueSet NHSN Platelets/Whole Blood Derived/Irradiated and Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7307) SHALL be used (CONF:3247-30759).
   24. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Whole Blood Derived/Leukocyte Reduced (3419-9, 3488-4), then valueSet NHSN Platelets/Whole Blood Derived/Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7306) SHALL be used (CONF:3247-30760).
   25. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Whole Blood Derived/Irradiated (3418-1, 3487-6), then valueSet NHSN Platelets/Whole Blood Derived/Irradiated (urn:oid:2.16.840.1.114222.4.11.7305) SHALL be used (CONF:3247-30761).
   26. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (3485-0, 3486-8), then valueSet NHSN Platelets/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7304) SHALL be used (CONF:3247-30762).
   27. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Apheresis/Irradiated or Leukocyte Reduced (3415-7, 3416-5, 3483-5), then valueSet NHSN Red Blood Cells/Apheresis/Irradiated or Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7302) SHALL be used (CONF:3247-30763).
   28. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Whole Blood Derived/Leukocyte Reduced (3405-8, 3406-6, 3475-1), then valueSet NHSN Red Blood Cells/Whole Blood Derived/Leukocyte Reduced (urn:oid:2.16.840.1.114222.4.11.7296) SHALL be used (CONF:3247-30767).
   29. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Whole Blood Derived/S-303-Treated (3547-7, 3548-5, 3549-3), then valueSet NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated (urn:oid:2.16.840.1.114222.4.11.7498) SHALL be used (CONF:3247-30769).
   30. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Whole Blood Derived/Riboflavin-Treated (3550-1, 3551-9, 3552-7), then valueSet NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated (urn:oid:2.16.840.1.114222.4.11.7499) SHALL be used (CONF:3247-30770).
   31. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Apheresis/S-303-Treated (3556-8, 3557-6, 3558-4), then valueSet NHSN Red Blood Cells/Apheresis/S-303-Treated (urn:oid:2.16.840.1.114222.4.11.7500) SHALL be used (CONF:3247-30771).
   32. If the product specified in the containing Blood Product Usage Summary Observation is Red Blood Cells/Apheresis/Riboflavin-Treated (3559-2, 3560-0, 3561-8), then valueSet NHSN Red Blood Cells/Apheresis/Riboflavin-Treated (urn:oid:2.16.840.1.114222.4.11.7501) SHALL be used (CONF:3247-30772).
   33. If the product specified in the containing Blood Product Usage Summary Observation is Cryoprecipitate/Psoralen-Treated (3564-2, 3565-9), then valueSet NHSN Cryoprecipitate/Psoralen-Treated (urn:oid:2.16.840.1.114222.4.11.7502) SHALL be used (CONF:3247-30773).
   34. If the product specified in the containing Blood Product Usage Summary Observation is Cryoprecipitate/Riboflavin-Treated (3566-7, 3567-5), then valueSet NHSN Cryoprecipitate/Riboflavin-Treated (urn:oid:2.16.840.1.114222.4.11.7503) SHALL be used (CONF:3247-30774).
   35. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Psoralen-Treated and In Plasma (3568-3, 3569-1, 3570-9), then valueSet NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma (urn:oid:2.16.840.1.114222.4.11.7504) SHALL be used (CONF:3247-30775).
   36. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution (3571-7, 3572-5, 3573-3), then valueSet NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution (urn:oid:2.16.840.1.114222.4.11.7505) SHALL be used (CONF:3247-30776).
   37. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Riboflavin-Treated and In Plasma (3574-1, 3575-8, 3576-6), then valueSet NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma (urn:oid:2.16.840.1.114222.4.11.7506) SHALL be used (CONF:3247-30777).
   38. If the product specified in the containing Blood Product Usage Summary Observation is Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution (3577-4, 3578-2, 3579-0), then valueSet NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution (urn:oid:2.16.840.1.114222.4.11.7507) SHALL be used (CONF:3247-30778).
2. SHALL contain exactly one [1..1] statusCode (CONF:3247-30718).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: HL7ActStatus urn:oid:2.16.840.1.113883.5.14) (CONF:3247-30722).
3. SHALL contain exactly one [1..1] value with @xsi:type="INT" (CONF:3247-30723).

Table 17: NHSN Whole Blood Total (1)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Whole Blood Total (1) urn:oid:2.16.840.1.114222.4.11.7292  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for Whole Blood Total reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0009 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | WHOLE BLOOD|CPD/450mL/refg |
| E0013 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | WHOLE BLOOD|CPD/450mL/refg|Open |
| ... | | | |

Table 18: NHSN Red Blood Cells/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (3)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (3) urn:oid:2.16.840.1.114222.4.11.7294  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Whole Blood Derived/Not Irradiated or Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0142 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|ACD-A/450mL/refg |
| E0146 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|ACD-B/450mL/refg |
| ... | | | |

Table 19: NHSN Red Blood Cells/Whole Blood Derived/Irradiated (4)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Whole Blood Derived/Irradiated (4) urn:oid:2.16.840.1.114222.4.11.7295  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Whole Blood Derived/Irradiated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0155 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|CPD/450mL/refg|Open|Irradiated |
| E0157 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|CPD/450mL/refg|Open|Irradiated|Plasma added |
| ... | | | |

Table 20: NHSN Red Blood Cells/Whole Blood Derived/Irradiated and Leukocyte Reduced (6)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Whole Blood Derived/Irradiated and Leukocyte Reduced (6) urn:oid:2.16.840.1.114222.4.11.7297  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Whole Blood Derived/Irradiated and Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0156 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|CPD/450mL/refg|Open|Irradiated|ResLeu:<5E6 |
| E0162 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|CPD/450mL/refg|Irradiated|ResLeu:<5E6 |
| ... | | | |

Table 21: NHSN Red Blood Cells/Whole Blood Derived/Leukocyte Reduced (5)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Whole Blood Derived/Leukocyte Reduced (5) urn:oid:2.16.840.1.114222.4.11.7296  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Whole Blood Derived/Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0158 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|CPD/450mL/refg|Open|ResLeu:<5E6 |
| E0164 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | RED BLOOD CELLS|CPD/450mL/refg|ResLeu:<5E6 |
| ... | | | |

Table 22: NHSN Red Blood Cells/Apheresis/Not Irradiated or Leukocyte Reduced (8)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Apheresis/Not Irradiated or Leukocyte Reduced (8) urn:oid:2.16.840.1.114222.4.11.7299  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Apheresis/Not Irradiated or Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0605 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg |
| E0624 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open |
| ... | | | |

Table 23: NHSN Red Blood Cells/Apheresis/Irradiated (9)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Apheresis/Irradiated (9) urn:oid:2.16.840.1.114222.4.11.7300  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Apheresis/Irradiated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0625 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|Irradiated |
| E0635 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|Irradiated|Supernat rem |
| ... | | | |

Table 24: NHSN Red Blood Cells/Apheresis/Leukocyte Reduced (10)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Apheresis/Leukocyte Reduced (10) urn:oid:2.16.840.1.114222.4.11.7301  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Apheresis/Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0643 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|ResLeu:<5E6 |
| E0644 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|ResLeu:<5E6|Supernat rem |
| ... | | | |

Table 25: NHSN Plasma/Apheresis/Riboflavin-Treated (36)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Plasma/Apheresis/Riboflavin-Treated (36) urn:oid:2.16.840.1.114222.4.11.7327  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Plasma/Apheresis/Riboflavin-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E6544 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis FRESH FROZEN PLASMA|ACD-A/XX/<-25C|Riboflavin-treated |
| E6545 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis FRESH FROZEN PLASMA|NaCitrate/XX/<-25C|Frozen <=6h|Riboflavin-treated |
| ... | | | |

Table 26: NHSN Plasma/Apheresis/Psoralen-Treated (35)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Plasma/Apheresis/Psoralen-Treated (35) urn:oid:2.16.840.1.114222.4.11.7326  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Plasma/Apheresis/Psoralen-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E4984 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis FRESH FROZEN PLASMA|CPD-50/XX/<-30C|Psoralen-treated |
| E5732 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis FRESH FROZEN PLASMA|CPD-50/XX/<-25 C|1st container|Psoralen-treated |
| ... | | | |

Table 27: NHSN Plasma/Whole Blood Derived/Riboflavin-Treated (33)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Plasma/Whole Blood Derived/Riboflavin-Treated (33) urn:oid:2.16.840.1.114222.4.11.7324  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Plasma/Whole Blood Derived/Riboflavin-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E6542 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | FRESH FROZEN PLASMA|CPDA-1/XX/<-25C|Riboflavin-treated |
| E6543 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLASMA|CPDA-1/XX/<-25C|Cryo reduced|Riboflavin-treated |
| ... | | | |

Table 28: NHSN Plasma/Whole Blood Derived/Psoralen-Treated (32)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Plasma/Whole Blood Derived/Psoralen-Treated (32) urn:oid:2.16.840.1.114222.4.11.7323  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Plasma/Whole Blood Derived/Psoralen-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E4983 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | POOLED PLASMA|CPD/450mL/<-30C|2 units|Psoralen-treated |
| E5735 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Liquid POOLED PLASMA|CPD/450mL/refg|2 units|Psoralen-treated |
| ... | | | |

Table 29: NHSN Platelets/Apheresis/Riboflavin-Treated (30)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Riboflavin-Treated (30) urn:oid:2.16.840.1.114222.4.11.7321  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Riboflavin-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E5748 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|ResLeu:<5E6|Riboflavin-treated |
| E5749 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|ResLeu:<5E6|1st container|Riboflavin-treated |
| ... | | | |

Table 30: NHSN Platelets/Apheresis/Psoralen-Treated (29)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Psoralen-Treated (29) urn:oid:2.16.840.1.114222.4.11.7320  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Psoralen-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E4977 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|PAS-C/XX/20-24C|ResLeu:<1E6|1st container|Approx 240 E9 plts|Psoralen-treated |
| E4979 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|PAS-C/XX/20-24C|ResLeu:<1E6|2nd container|Approx 240 E9 plts|Psoralen-treated |
| ... | | | |

Table 31: NHSN Platelets/Whole Blood Derived/Riboflavin-Treated (27)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Whole Blood Derived/Riboflavin-Treated (27) urn:oid:2.16.840.1.114222.4.11.7318  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Whole Blood Derived/Riboflavin-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E5772 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | POOLED PLATELETS|CPD/XX/20-24C|ResLeu:<1E6|Riboflavin-treated |
| E5773 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | POOLED PLATELETS|CPD/XX/20-24C|Irradiated|ResLeu:<1E6|Riboflavin-treated |
| ... | | | |

Table 32: NHSN Platelets/Whole Blood Derived/Psoralen-Treated (26)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Whole Blood Derived/Psoralen-Treated (26) urn:oid:2.16.840.1.114222.4.11.7317  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Whole Blood Derived/Psoralen-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E4975 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | POOLED PLATELETS|PAS-C/XX/20-24C|ResLeu:<1E6|Buffy coat plts prep|Approx 240 E9 plts|Psoralen-treated |
| E5297 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | POOLED PLATELETS|CPD>PAS-C/XX/20-24C|ResLeu:<1E6|Buffy coat plts prep|Approx 240 E9 plts|Psoralen-treated |
| ... | | | |

Table 33: NHSN Cryoprecipitate (24)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Cryoprecipitate (24) urn:oid:2.16.840.1.114222.4.11.7315  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Cryoprecipitate reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E3571 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | CRYOPRECIPITATE|None/450mL/<=-18C |
| E3572 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | CRYOPRECIPITATE|None/450mL/<=-18C|Irradiated |
| ... | | | |

Table 34: NHSN Plasma/Apheresis/Total (23)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Plasma/Apheresis/Total (23) urn:oid:2.16.840.1.114222.4.11.7314  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Plasma/Apheresis/Total reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0829 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis FRESH FROZEN PLASMA|ACD-B/XX/<=-18C |
| E0838 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis FRESH FROZEN PLASMA|ACD-B/XX/<=-18C|Irradiated |
| ... | | | |

Table 35: NHSN Plasma/Whole Blood Derived/Total (22)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Plasma/Whole Blood Derived/Total (22) urn:oid:2.16.840.1.114222.4.11.7313  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Plasma/Whole Blood Derived/Total reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0695 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | FRESH FROZEN PLASMA|ACD-B/XX/<=-18C |
| E0698 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | FRESH FROZEN PLASMA|ACD-B/XX/<=-18C|Irradiated |
| ... | | | |

Table 36: NHSN Platelets/Apheresis/Irradiated or Leukocyte Reduced (21)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Irradiated or Leukocyte Reduced (21) urn:oid:2.16.840.1.114222.4.11.7312  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Irradiated or Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E2983 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|Open|Irradiated|ResLeu:<5E6 |
| E2984 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced |
| ... | | | |

Table 37: NHSN Platelets/Apheresis/Leukocyte Reduced (20)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Leukocyte Reduced (20) urn:oid:2.16.840.1.114222.4.11.7311  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E3014 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|Open|ResLeu:<5E6 |
| E3015 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced |
| ... | | | |

Table 38: NHSN Platelets/Apheresis/Irradiated (19)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Irradiated (19) urn:oid:2.16.840.1.114222.4.11.7310  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Irradiated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E2982 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|Open|Irradiated |
| E2999 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|Open|Irradiated|Plasma reduced |
| ... | | | |

Table 39: NHSN Platelets/Apheresis/Not Irradiated or Leukocyte Reduced (18)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Not Irradiated or Leukocyte Reduced (18) urn:oid:2.16.840.1.114222.4.11.7309  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Not Irradiated or Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E2922 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-B/XX/refg |
| E2926 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/refg |
| ... | | | |

Table 40: NHSN Platelets/Whole Blood Derived/Irradiated and Leukocyte Reduced (16)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Whole Blood Derived/Irradiated and Leukocyte Reduced (16) urn:oid:2.16.840.1.114222.4.11.7307  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Whole Blood Derived/Irradiated and Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E2810 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPD/450mL/20-24C|Irradiated|ResLeu:<8.3E5 |
| E2811 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPD/450mL/20-24C|Irradiated|ResLeu:<8.3E5|Plasma reduced |
| ... | | | |

Table 41: NHSN Platelets/Whole Blood Derived/Leukocyte Reduced (15)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Whole Blood Derived/Leukocyte Reduced (15) urn:oid:2.16.840.1.114222.4.11.7306  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Whole Blood Derived/Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E2817 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPD/450mL/20-24C|ResLeu:<8.3E5 |
| E2818 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPD/450mL/20-24C|ResLeu:<8.3E5|Plasma reduced |
| ... | | | |

Table 42: NHSN Platelets/Whole Blood Derived/Irradiated (14)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Whole Blood Derived/Irradiated (14) urn:oid:2.16.840.1.114222.4.11.7305  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Whole Blood Derived/Irradiated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E2809 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPD/450mL/20-24C|Irradiated |
| E2814 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPD/450mL/20-24C|Irradiated|Plasma reduced |
| ... | | | |

Table 43: NHSN Platelets/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (13)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (13) urn:oid:2.16.840.1.114222.4.11.7304  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Whole Blood Derived/Not Irradiated or Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E2790 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPD/450mL/refg |
| E2794 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | PLATELETS|CPDA-1/450mL/refg |
| ... | | | |

Table 44: NHSN Red Blood Cells/Apheresis/Irradiated or Leukocyte Reduced (11)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Apheresis/Irradiated or Leukocyte Reduced (11) urn:oid:2.16.840.1.114222.4.11.7302  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Apheresis/Irradiated or Leukocyte Reduced reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E0626 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|Irradiated|ResLeu:<5E6 |
| E0627 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|Irradiated|ResLeu:<5E6|Supernat rem |
| ... | | | |

Table 45: NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated urn:oid:2.16.840.1.114222.4.11.7498  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| NA\_RBC\_WBD\_S-303 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated: no codes available at this time please check with NHSN for updates |

Table 46: NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated urn:oid:2.16.840.1.114222.4.11.7499  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| NA\_RBC\_WBD\_Riboflavin | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated: no codes available at this time please check with NHSN for updates |

Table 47: NHSN Red Blood Cells/Apheresis/S-303-Treated (41)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Apheresis/S-303-Treated (41) urn:oid:2.16.840.1.114222.4.11.7500  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Apheresis/S-303-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| NA\_RBC\_APH\_S-303 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | NHSN Red Blood Cells/Apheresis/S-303-Treated: no codes available at this time please check with NHSN for updates |

Table 48: NHSN Red Blood Cells/Apheresis/Riboflavin-Treated (42)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Red Blood Cells/Apheresis/Riboflavin-Treated (42) urn:oid:2.16.840.1.114222.4.11.7501  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Red Blood Cells/Apheresis/Riboflavin-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| NA\_RBC\_APH\_Riboflavin | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | NHSN Red Blood Cells/Apheresis/Riboflavin-Treated: no codes available at this time please check with NHSN for any updates |

Table 49: NHSN Cryoprecipitate/Psoralen-Treated (44)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Cryoprecipitate/Psoralen-Treated (44) urn:oid:2.16.840.1.114222.4.11.7502  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Cryoprecipitate/Psoralen-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E9288 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Thawed POOLED CRYOPRECIPITATE|CPD/XX/rt|3 units|Psoralen-treated|From 3 donors |

Table 50: NHSN Cryoprecipitate/Riboflavin-Treated (45)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Cryoprecipitate/Riboflavin-Treated (45) urn:oid:2.16.840.1.114222.4.11.7503  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Cryoprecipitate/Riboflavin-Treated reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E7072 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | CRYOPRECIPITATE|CPD/450mL/<=-25C|Riboflavin-treated |
| E7073 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | CRYOPRECIPITATE|CPDA-1/450mL/<=-25C|Riboflavin-treated |
| ... | | | |

Table 51: NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma (46)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma (46) urn:oid:2.16.840.1.114222.4.11.7504  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E5870 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Washed Apheresis PLATELETS|None/XX/20-24C|ResLeu:<1E6|1st container|Psoralen-treated |
| E5871 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Washed Apheresis PLATELETS|None/XX/20-24C|ResLeu:<1E6|2nd container|Psoralen-treated |
| ... | | | |

Table 52: NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution (47)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution (47) urn:oid:2.16.840.1.114222.4.11.7505  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E4977 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|PAS-C/XX/20-24C|ResLeu:<1E6|1st container|Approx 240 E9 plts|Psoralen-treated |
| E4979 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|PAS-C/XX/20-24C|ResLeu:<1E6|2nd container|Approx 240 E9 plts|Psoralen-treated |
| ... | | | |

Table 53: NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma (48)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma (48) urn:oid:2.16.840.1.114222.4.11.7506  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E5748 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|ResLeu:<5E6|Riboflavin-treated |
| E5749 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|ACD-A/XX/20-24C|ResLeu:<5E6|1st container|Riboflavin-treated |
| ... | | | |

Table 54: NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution (49)

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution (49) urn:oid:2.16.840.1.114222.4.11.7507  NHSN Protocol specifies which ISBT Blood Product codes to use for each blood product type.  The ISBT blood product codes for NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution reporting, at the time of publication, are contained in this value set.  A full listing of codes in this value set can be sourced from NHSN. | | | |
| Code | Code System | Code System OID | Print Name |
| E6641 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|PAS-E/XX/20-24C|ResLeu:<1E6|Riboflavin-treated |
| E7039 | ISBT-128 | urn:oid:2.16.840.1.113883.6.18 | Apheresis PLATELETS|PAS-E/XX/20-24C|ResLeu:<1E6|Supernat reduced|1st container|Riboflavin-treated |
| ... | | | |

Figure 27: ISBT Product Code Summary Observation Example

<observation classCode="OBS" moodCode="EVN">

<!-- ISBT Product Code Summary Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.238"

extension="2015-10-01" />

<code codeSystem="2.16.840.1.113883.6.18"

codeSystemName="ISBT-128" code="E0009"

displayName="WHOLE BLOOD|CPD/450mL/refg" />

<statusCode code="completed" />

<value xsi:type="INT" value="2" />

</observation>

No Hemovigilance Adverse Reactions Reported This Month Observation

[observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.232:2015-10-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1 - US Realm

Table 55: No Hemovigilance Adverse Reactions Reported This Month Observation Contexts

| Contained By: | Contains: |
| --- | --- |
| [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) (required) |  |

This clinical statement represents whether or not there were no hemovigilance adverse reactions reported this month.

If there were no hemovigilance adverse reactions reported this month, set the value of @negationInd to false, otherwise, set the value of @negationInd to true.

On the form from which this template is modeled, this datum is reported as a check box stating that there were no hemovigilance adverse reactions reported this month. Thus, this template reports a "negative" finding. To report that this check box was not checked is to say that it is not the case that no hemovigilance adverse reactions were reported this month, which is subtly different from stating that there were hemovigilance adverse reactions reported this month. Because we are reporting a "negative" finding, negating the statement necessitates some seemingly counter-intuitive logic as follows:

* No hemovigilance adverse reactions reported this month = ASSERTION + negationInd="false" (the assertion that there were no HV adverse reactions is not negated)
* Otherwise = ASSERTION + negationInd="true" (the assertion that there were no HV adverse reactions is negated).

Table 56: No Hemovigilance Adverse Reactions Reported This Month Observation Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.232:2015-10-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [1202-30632](#C_1202-30632) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | [1202-30633](#C_1202-30633) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| @negationInd | 1..1 | SHALL |  | [1202-30634](#C_1202-30634) |  |
| templateId | 1..1 | SHALL |  | [1202-30627](#C_1202-30627) |  |
| @root | 1..1 | SHALL |  | [1202-30635](#C_1202-30635) | 2.16.840.1.113883.10.20.5.6.232 |
| @extension | 1..1 | SHALL |  | [1202-30636](#C_1202-30636) | 2015-10-01 |
| code | 1..1 | SHALL |  | [1202-30624](#C_1202-30624) |  |
| @code | 1..1 | SHALL | CS | [1202-30628](#C_1202-30628) | ASSERTION |
| @codeSystem | 1..1 | SHALL |  | [1202-30629](#C_1202-30629) | urn:oid:2.16.840.1.113883.5.4 (HL7ActCode) = 2.16.840.1.113883.5.4 |
| statusCode | 1..1 | SHALL |  | [1202-30625](#C_1202-30625) |  |
| @code | 1..1 | SHALL |  | [1202-30630](#C_1202-30630) | urn:oid:2.16.840.1.113883.5.14 (HL7ActStatus) = completed |
| value | 1..1 | SHALL | CD | [1202-30626](#C_1202-30626) |  |
| @code | 1..1 | SHALL |  | [1202-30631](#C_1202-30631) | 3540-2 |
| @codeSystem | 1..1 | SHALL |  | [1202-30651](#C_1202-30651) | urn:oid:2.16.840.1.113883.6.277 (cdcNHSN) = 2.16.840.1.113883.6.277 |

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6 STATIC) (CONF:1202-30632).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001 STATIC) (CONF:1202-30633).

If there were no hemovigilance adverse reactions reported this month, set the value of @negationInd to false. If there were hemovigilance adverse reactions reported this month, set the value of @negationInd to true.

1. SHALL contain exactly one [1..1] @negationInd (CONF:1202-30634).
2. SHALL contain exactly one [1..1] templateId (CONF:1202-30627) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.232" (CONF:1202-30635).
   2. SHALL contain exactly one [1..1] @extension="2015-10-01" (CONF:1202-30636).
3. SHALL contain exactly one [1..1] code (CONF:1202-30624).
   1. This code SHALL contain exactly one [1..1] @code="ASSERTION" Assertion (CONF:1202-30628).
   2. This code SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.5.4" (CodeSystem: HL7ActCode urn:oid:2.16.840.1.113883.5.4) (CONF:1202-30629).
4. SHALL contain exactly one [1..1] statusCode (CONF:1202-30625).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: HL7ActStatus urn:oid:2.16.840.1.113883.5.14 STATIC) (CONF:1202-30630).
5. SHALL contain exactly one [1..1] value with @xsi:type="CD" (CONF:1202-30626).
   1. This value SHALL contain exactly one [1..1] @code="3540-2" No hemovigilance adverse reactions reported this month (CONF:1202-30631).
   2. This value SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.6.277" (CodeSystem: cdcNHSN urn:oid:2.16.840.1.113883.6.277) (CONF:1202-30651).

Figure 28: No Hemovigilance Adverse Reactions Reported This Month Observation Example

<!-- If there were no hemovigilance adverse reactions reported this month,

set the value of @negationInd to false.

If there were hemovigilance adverse reactions reported this month,

set the value of @negationInd to true. -->

<!-- There were no hemovigilance adverse reactions reported this month so negationInd='false' -->

<observation classCode="OBS" moodCode="EVN" negationInd="false">

<!-- No Hemovigilance Adverse Reactions Reported This Month Observation templateId -->

<templateId root="2.16.840.1.113883.10.20.5.6.232"

extension="2015-10-01" />

<code code="ASSERTION"

codeSystem="2.16.840.1.113883.5.4" />

<statusCode code="completed"/>

<value xsi:type="CD"

codeSystem="2.16.840.1.113883.6.277"

codeSystemName="cdcNHSN"

code="3540-2"

displayName="No hemovigilance adverse reactions reported this month" />

</observation>

No Hemovigilance Incidents Reported This Month Observation

[observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.233:2015-10-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1 - US Realm

Table 57: No Hemovigilance Incidents Reported This Month Observation Contexts

| Contained By: | Contains: |
| --- | --- |
| [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) (required) |  |

This clinical statement represents whether or not there were no hemovigilance incidents reported this month.

If there were no hemovigilance incidents reported this month, set the value of @negationInd to false, otherwise, set the value of @negationInd to true.

On the form from which this template is modeled, this datum is reported as a check box stating that there were no incidents reported this month. Thus, this template reports a "negative" finding. To report that this check box was not checked is to say that it is not the case that no hemovigilance incidents were reported this month, which is subtly different from stating that there were hemovigilance incidents reported this month. Because we are reporting a "negative" finding, negating the statement necessitates some seemingly counter-intuitive logic as follows:

* No hemovigilance incidents reported this month = ASSERTION + negationInd="false" (the assertion that there were no HV incidents is not negated)
* Otherwise = ASSERTION + negationInd="true" (the assertion that there were no HV incidents is negated).

Table 58: No Hemovigilance Incidents Reported This Month Observation Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.233:2015-10-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [1202-30647](#C_1202-30647) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | [1202-30648](#C_1202-30648) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| @negationInd | 1..1 | SHALL |  | [1202-30649](#C_1202-30649) |  |
| templateId | 1..1 | SHALL |  | [1202-30640](#C_1202-30640) |  |
| @root | 1..1 | SHALL |  | [1202-30645](#C_1202-30645) | 2.16.840.1.113883.10.20.5.6.233 |
| @extension | 1..1 | SHALL |  | [1202-30646](#C_1202-30646) | 2015-10-01 |
| code | 1..1 | SHALL |  | [1202-30637](#C_1202-30637) |  |
| @code | 1..1 | SHALL | CS | [1202-30641](#C_1202-30641) | ASSERTION |
| @codeSystem | 1..1 | SHALL |  | [1202-30642](#C_1202-30642) | urn:oid:2.16.840.1.113883.5.4 (HL7ActCode) = 2.16.840.1.113883.5.4 |
| statusCode | 1..1 | SHALL |  | [1202-30638](#C_1202-30638) |  |
| @code | 1..1 | SHALL |  | [1202-30643](#C_1202-30643) | urn:oid:2.16.840.1.113883.5.14 (HL7ActStatus) = completed |
| value | 1..1 | SHALL | CD | [1202-30639](#C_1202-30639) |  |
| @code | 1..1 | SHALL |  | [1202-30644](#C_1202-30644) | 3541-0 |
| @codeSystem | 1..1 | SHALL |  | [1202-30650](#C_1202-30650) | urn:oid:2.16.840.1.113883.6.277 (cdcNHSN) = 2.16.840.1.113883.6.277 |

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6 STATIC) (CONF:1202-30647).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001 STATIC) (CONF:1202-30648).

If there were no hemovigilance incidents reported this month, set the value of @negationInd to false. If there were hemovigilance incidents reported this month, set the value of @negationInd to true.

1. SHALL contain exactly one [1..1] @negationInd (CONF:1202-30649).
2. SHALL contain exactly one [1..1] templateId (CONF:1202-30640) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.233" (CONF:1202-30645).
   2. SHALL contain exactly one [1..1] @extension="2015-10-01" (CONF:1202-30646).
3. SHALL contain exactly one [1..1] code (CONF:1202-30637).
   1. This code SHALL contain exactly one [1..1] @code="ASSERTION" Assertion (CONF:1202-30641).
   2. This code SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.5.4" (CodeSystem: HL7ActCode urn:oid:2.16.840.1.113883.5.4) (CONF:1202-30642).
4. SHALL contain exactly one [1..1] statusCode (CONF:1202-30638).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: HL7ActStatus urn:oid:2.16.840.1.113883.5.14 STATIC) (CONF:1202-30643).
5. SHALL contain exactly one [1..1] value with @xsi:type="CD" (CONF:1202-30639).
   1. This value SHALL contain exactly one [1..1] @code="3541-0" No hemovigilance incidents reported this month (CONF:1202-30644).
   2. This value SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.6.277" (CodeSystem: cdcNHSN urn:oid:2.16.840.1.113883.6.277) (CONF:1202-30650).

Figure 29: No Hemovigilance Incidents Reported This Month Observation

<!-- No Hemovigilance Incidents Reported This Month Observation -->

<!-- If there were no hemovigilance incidents reported this month,

set the value of @negationInd to false.

If there were hemovigilance incidents reported this month,

set the value of @negationInd to true. -->

<!-- There were hemovigilance incidents reported this month so negationInd='true' -->

<observation classCode="OBS" moodCode="EVN" negationInd="true">

<!-- No Hemovigilance Incidents Reported This Month Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.233"

extension="2015-10-01" />

<code code="ASSERTION"

codeSystem="2.16.840.1.113883.5.4" />

<statusCode code="completed"/>

<value xsi:type="CD"

codeSystem="2.16.840.1.113883.6.277"

codeSystemName="cdcNHSN" code="3541-0"

displayName="No hemovigilance incidents reported this month" />

</observation>

Pathogen Reduced Apheresis Platelet Usage Summary Observation

[observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.240:2016-08-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1 - US Realm

Table 59: Pathogen Reduced Apheresis Platelet Usage Summary Observation Contexts

| Contained By: | Contains: |
| --- | --- |
| [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) (optional) | [ISBT Product Code Summary Observation (V2)](#E_ISBT_Product_Code_Summary_ObsV2) (optional) |

This template represents the number of units transfused, aliquots transfused, or total discards for pathogen reduced apheresis platelets.

If the value = 0, there *SHALL NOT* be a contained observation. If the value is > 0 then each specific subcategory product that is > 0 *SHALL* be listed in a separate contained ISBT Product Code Summary Observation.

Table 60: Pathogen Reduced Apheresis Platelet Usage Summary Observation Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.240:2016-08-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [3247-30789](#C_3247-30789) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | [3247-30790](#C_3247-30790) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| templateId | 1..1 | SHALL |  | [3247-30780](#C_3247-30780) |  |
| @root | 1..1 | SHALL |  | [3247-30784](#C_3247-30784) | 2.16.840.1.113883.10.20.5.6.240 |
| @extension | 1..1 | SHALL |  | [3247-30785](#C_3247-30785) | 2016-08-01 |
| code | 1..1 | SHALL |  | [3247-30781](#C_3247-30781) |  |
| @code | 1..1 | SHALL |  | [3247-30786](#C_3247-30786) | urn:oid:2.16.840.1.113883.10.20.5.9.5 (NHSN Pathogen Reduced Apheresis Platelet Usage) |
| statusCode | 1..1 | SHALL |  | [3247-30782](#C_3247-30782) |  |
| @code | 1..1 | SHALL |  | [3247-30787](#C_3247-30787) | urn:oid:2.16.840.1.113883.5.14 (HL7ActStatus) = completed |
| value | 1..1 | SHALL | INT | [3247-30788](#C_3247-30788) |  |
| entryRelationship | 0..\* | SHOULD |  | [3247-30779](#C_3247-30779) |  |
| observation | 1..1 | SHALL |  | [3247-30783](#C_3247-30783) | [ISBT Product Code Summary Observation (V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01](#E_ISBT_Product_Code_Summary_ObsV2) |

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6) (CONF:3247-30789).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001) (CONF:3247-30790).
3. SHALL contain exactly one [1..1] templateId (CONF:3247-30780) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.240" (CONF:3247-30784).
   2. SHALL contain exactly one [1..1] @extension="2016-08-01" (CONF:3247-30785).
4. SHALL contain exactly one [1..1] code (CONF:3247-30781).
   1. This code SHALL contain exactly one [1..1] @code, which SHALL be selected from ValueSet [NHSN Pathogen Reduced Apheresis Platelet Usage](#NHSN_Pathogen_Reduced_Apheresis_Platele) urn:oid:2.16.840.1.113883.10.20.5.9.5 DYNAMIC (CONF:3247-30786).
5. SHALL contain exactly one [1..1] statusCode (CONF:3247-30782).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: HL7ActStatus urn:oid:2.16.840.1.113883.5.14) (CONF:3247-30787).
6. SHALL contain exactly one [1..1] value with @xsi:type="INT" (CONF:3247-30788).
7. SHOULD contain zero or more [0..\*] entryRelationship (CONF:3247-30779).
   1. The entryRelationship, if present, SHALL contain exactly one [1..1] [ISBT Product Code Summary Observation (V2)](#E_ISBT_Product_Code_Summary_ObsV2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01) (CONF:3247-30783).
8. If the value = 0 there SHALL NOT be a contained observation. If the value is > 0 then each specific subcategory product that is > 0 SHALL be listed in a separate contained ISBT Product Code Summary Observation (CONF:3247-30791).

Table 61: NHSN Pathogen Reduced Apheresis Platelet Usage

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: NHSN Pathogen Reduced Apheresis Platelet Usage urn:oid:2.16.840.1.113883.10.20.5.9.5  (Clinical Focus: NHSN surveillance reporting: monthly reporting denominators for hemovigilance),(Data Element Scope: Code identifying the type of observation.),(Inclusion Criteria: ),(Exclusion Criteria: )  This value set was imported on 10/14/2020 with a version of Latest.  Value Set Source: <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.10.20.5.9.5/expansion> | | | |
| Code | Code System | Code System OID | Print Name |
| 3568-3 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Number of units transfused: Platelets: Apheresis: Psoralen-treated and in plasma |
| 3569-1 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated and in plasma |
| ... | | | |

Figure 30: Pathogen Reduced Apheresis Platelet Usage Summary Example

<observation classCode="OBS" moodCode="EVN">

<!-- [HAI R3D1.1] Pathogen Reduced Apheresis Platelet Usage Summary Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.240" extension="2016-08-01" />

<code codeSystem="2.16.840.1.113883.6.277"

codeSystemName="cdcNHSN"

code="3571-7"

displayName="Number of units transfused - Platelets/Apheresis/Psoralen-Treated and in Platelet Additive Solution" />

<statusCode code="completed" />

<value xsi:type="INT" value="75" />

<!--

If the value = 0, there SHALL NOT be a contained observation.

If the value is > 0 then each specific subcategory product that is > 0

SHALL be listed in a separate contained ISBT Product Code Summary Observation.

-->

<entryRelationship typeCode="COMP">

<observation classCode="OBS" moodCode="EVN">

<!-- ISBT Product Code Summary Observation (V2) -->

<templateId root="2.16.840.1.113883.10.20.5.6.238" extension="2016-08-01" />

...

</observation>

</entryRelationship>

...

</observation>

Summary Data Observation (HV)

[observation: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.235:2015-10-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1 - US Realm

Table 62: Summary Data Observation (HV) Contexts

| Contained By: | Contains: |
| --- | --- |
| [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) (required) |  |

This template specializes the Summary Data Observation for an HAI Hemovigilance (HV) Summary Report.

The documentationOf/serviceEvent/code in the header identifies the intended content of the report. NHSN protocol specifies which data to report for each type of content. The data required by NHSN for each type of content, at time of publication, are shown in the tables below.

The table of codes for a particular report indicate what data are required at time of publication for the NHSN protocol. Accordingly, the Summary Encounter will contain the same number of Summary Data Observations as codes in the table.

Most Summary Data Observations are a simple code-value pair. The code element identifies the datum being reported, and the value element records a number of days, patients, episodes, or events.

Table 63: Summary Data Observation (HV) Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.235:2015-10-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [1202-30675](#C_1202-30675) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = OBS |
| @moodCode | 1..1 | SHALL |  | [1202-30676](#C_1202-30676) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| templateId | 1..1 | SHALL |  | [1202-30671](#C_1202-30671) |  |
| @root | 1..1 | SHALL |  | [1202-30677](#C_1202-30677) | 2.16.840.1.113883.10.20.5.6.235 |
| @extension | 1..1 | SHALL |  | [1202-30684](#C_1202-30684) | 2015-10-01 |
| code | 1..1 | SHALL |  | [1202-30672](#C_1202-30672) | urn:oid:2.16.840.1.113883.10.20.5.9.11 (Codes for Hemovigilance (HV) Summary Data) |
| statusCode | 1..1 | SHALL |  | [1202-30673](#C_1202-30673) |  |
| @code | 1..1 | SHALL |  | [1202-30683](#C_1202-30683) | urn:oid:2.16.840.1.113883.5.14 (HL7ActStatus) = completed |
| value | 1..1 | SHALL | INT | [1202-30674](#C_1202-30674) |  |

1. SHALL contain exactly one [1..1] @classCode="OBS" Observation (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6) (CONF:1202-30675).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001) (CONF:1202-30676).
3. SHALL contain exactly one [1..1] templateId (CONF:1202-30671) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.235" (CONF:1202-30677).
   2. SHALL contain exactly one [1..1] @extension="2015-10-01" (CONF:1202-30684).
4. SHALL contain exactly one [1..1] code, which SHOULD be selected from ValueSet [Codes for Hemovigilance (HV) Summary Data](#Codes_for_Hemovigilance_HV_Summary_Data) urn:oid:2.16.840.1.113883.10.20.5.9.11 DYNAMIC (CONF:1202-30672).
5. SHALL contain exactly one [1..1] statusCode (CONF:1202-30673).
   1. This statusCode SHALL contain exactly one [1..1] @code="completed" Completed (CodeSystem: HL7ActStatus urn:oid:2.16.840.1.113883.5.14) (CONF:1202-30683).
6. SHALL contain exactly one [1..1] value with @xsi:type="INT" (CONF:1202-30674).

Table 64: Codes for Hemovigilance (HV) Summary Data

|  |  |  |  |
| --- | --- | --- | --- |
| Value Set: Codes for Hemovigilance (HV) Summary Data urn:oid:2.16.840.1.113883.10.20.5.9.11  (Clinical Focus: NHSN surveillance reporting: monthly reporting denominators for hemovigilance),(Data Element Scope: Code identifying the type of observation.),(Inclusion Criteria: ),(Exclusion Criteria: )  This value set was imported on 10/14/2020 with a version of Latest.  Value Set Source: <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.10.20.5.9.11/expansion> | | | |
| Code | Code System | Code System OID | Print Name |
| 3436-3 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Number of patient samples collected for type and screen or crossmatch |
| 3538-6 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Total crossmatch procedures |
| 3539-4 | cdcNHSN | urn:oid:2.16.840.1.113883.6.277 | Total patients transfused |

Figure 31: Summary Data Observation (HV) Example

<observation classCode="OBS" moodCode="EVN">

<!-- Summary Data Observation (HV) -->

<templateId root="2.16.840.1.113883.10.20.5.6.235"

extension="2015-10-01" />

<code codeSystem="2.16.840.1.113883.6.277"

codeSystemName="cdcNHSN"

code="3539-4"

displayName="Total patients transfused" />

<statusCode code="completed" />

<value xsi:type="INT" value="74" />

</observation>

Summary Encounter (HV) (V2)

[encounter: identifier urn:hl7ii:2.16.840.1.113883.10.20.5.6.234:2016-08-01 (closed)]

Published as part of NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1 - US Realm

Table 65: Summary Encounter (HV) (V2) Contexts

| Contained By: | Contains: |
| --- | --- |
| [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) (required) | [Summary Data Observation (HV)](#E_Summary_Data_Observation_HV) (required)  [Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2)](#E_Facility_Transfuses_Blood_Products_Tr) (required)  [Blood Product Usage Summary Observation (V2)](#E_Blood_Product_Usage_Summary_Obs_V2) (required)  [Pathogen Reduced Apheresis Platelet Usage Summary Observation](#E_Pathogen_Reduced_Apheresis_Platelet_U) (optional) |

A Summary Encounter records a set of summary data, usually for a population such as the patients in a ward in a specified period. The NHSN protocol defines which data to record for each type of summary report.

For a Hemovigilance Summary Report, each datum is recorded as a Summary Data Observation (HV). The data requirements at time of publication are shown in a table under the Summary Data Observation (HV) template, above.

The Summary Encounter (HV) includes a Blood Product Usage Summary Observation for each type of blood product being reported and, conditionally (if the facility transfused pathogen reduced apheresis platelets), a Pathogen Reduced Apheresis Platelet Usage Summary Observation for each type of pathogen reduced apheresis platelet being reported.

A participant element records the location to which the data pertains. The location id has the form <id root=”…” extension=”…”/> with an extension of 'FACWIDEIN' representing the whole facility.

Table 66: Summary Encounter (HV) (V2) Constraints Overview

| XPath | Card. | Verb | Data Type | CONF# | Value |
| --- | --- | --- | --- | --- | --- |
| encounter (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.234:2016-08-01) | | | | | |
| @classCode | 1..1 | SHALL |  | [3247-30669](#C_3247-30669) | urn:oid:2.16.840.1.113883.5.6 (HL7ActClass) = ENC |
| @moodCode | 1..1 | SHALL |  | [3247-30670](#C_3247-30670) | urn:oid:2.16.840.1.113883.5.1001 (HL7ActMood) = EVN |
| templateId | 1..1 | SHALL |  | [3247-30653](#C_3247-30653) |  |
| @root | 1..1 | SHALL |  | [3247-30660](#C_3247-30660) | 2.16.840.1.113883.10.20.5.6.234 |
| @extension | 1..1 | SHALL |  | [3247-30661](#C_3247-30661) | 2016-08-01 |
| participant | 1..1 | SHALL |  | [3247-30654](#C_3247-30654) |  |
| @typeCode | 1..1 | SHALL |  | [3247-30668](#C_3247-30668) | urn:oid:2.16.840.1.113883.5.90 (HL7ParticipationType) = LOC |
| participantRole | 1..1 | SHALL |  | [3247-30655](#C_3247-30655) |  |
| @classCode | 1..1 | SHALL |  | [3247-30667](#C_3247-30667) | urn:oid:2.16.840.1.113883.5.41 (HL7EntityClass) = SDLOC |
| id | 1..1 | SHALL |  | [3247-30656](#C_3247-30656) |  |
| @root | 1..1 | SHALL |  | [3247-30662](#C_3247-30662) |  |
| @extension | 1..1 | SHALL |  | [3247-30663](#C_3247-30663) | FACWIDEIN |
| code | 1..1 | SHALL |  | [3247-30657](#C_3247-30657) | urn:oid:2.16.840.1.113883.6.259 (HSLOC) |
| @code | 1..1 | SHALL |  | [3247-30664](#C_3247-30664) | 1250-0 |
| @codeSystem | 1..1 | SHALL |  | [3247-30665](#C_3247-30665) | 2.16.840.1.113883.6.259 |
| @displayName | 1..1 | SHOULD |  | [3247-30666](#C_3247-30666) | Facility Wide Inpatient |
| entryRelationship | 1..\* | SHALL |  | [3247-30652](#C_3247-30652) |  |
| @typeCode | 1..1 | SHALL |  | [3247-30659](#C_3247-30659) | urn:oid:2.16.840.1.113883.5.1002 (HL7ActRelationshipType) = COMP |
| observation | 1..1 | SHALL |  | [3247-30658](#C_3247-30658) | [Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.236:2016-08-01](#E_Facility_Transfuses_Blood_Products_Tr) |
| entryRelationship | 1..\* | SHALL |  | [3247-30733](#C_3247-30733) |  |
| @typeCode | 1..1 | SHALL |  | [3247-30734](#C_3247-30734) | COMP |
| observation | 1..1 | SHALL |  | [3247-30735](#C_3247-30735) | [Blood Product Usage Summary Observation (V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.237:2016-08-01](#E_Blood_Product_Usage_Summary_Obs_V2) |
| entryRelationship | 0..\* | MAY |  | [3247-30792](#C_3247-30792) |  |
| observation | 1..1 | SHALL |  | [3247-30793](#C_3247-30793) | [Pathogen Reduced Apheresis Platelet Usage Summary Observation (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.240:2016-08-01](#E_Pathogen_Reduced_Apheresis_Platelet_U) |
| entryRelationship | 1..\* | SHALL |  | [3247-30730](#C_3247-30730) |  |
| @typeCode | 1..1 | SHALL |  | [3247-30731](#C_3247-30731) | COMP |
| observation | 1..1 | SHALL |  | [3247-30732](#C_3247-30732) | [Summary Data Observation (HV) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.235:2015-10-01](#E_Summary_Data_Observation_HV) |

1. SHALL contain exactly one [1..1] @classCode="ENC" Encounter (CodeSystem: HL7ActClass urn:oid:2.16.840.1.113883.5.6 STATIC) (CONF:3247-30669).
2. SHALL contain exactly one [1..1] @moodCode="EVN" Event (CodeSystem: HL7ActMood urn:oid:2.16.840.1.113883.5.1001 STATIC) (CONF:3247-30670).
3. SHALL contain exactly one [1..1] templateId (CONF:3247-30653) such that it
   1. SHALL contain exactly one [1..1] @root="2.16.840.1.113883.10.20.5.6.234" (CONF:3247-30660).
   2. SHALL contain exactly one [1..1] @extension="2016-08-01" (CONF:3247-30661).
4. SHALL contain exactly one [1..1] participant (CONF:3247-30654) such that it
   1. SHALL contain exactly one [1..1] @typeCode="LOC" Location (CodeSystem: HL7ParticipationType urn:oid:2.16.840.1.113883.5.90 STATIC) (CONF:3247-30668).
   2. SHALL contain exactly one [1..1] participantRole (CONF:3247-30655).
      1. This participantRole SHALL contain exactly one [1..1] @classCode="SDLOC" Service Delivery Location (CodeSystem: HL7EntityClass urn:oid:2.16.840.1.113883.5.41 STATIC) (CONF:3247-30667).
      2. This participantRole SHALL contain exactly one [1..1] id (CONF:3247-30656).

The value of @root must be the NHSN assigned Facility OID.

* + - 1. This id SHALL contain exactly one [1..1] @root (CONF:3247-30662).

The value of @extension must be a value registered with NHSN.

* + - 1. This id SHALL contain exactly one [1..1] @extension="FACWIDEIN" (CONF:3247-30663).
    1. This participantRole SHALL contain exactly one [1..1] code (CodeSystem: HSLOC urn:oid:2.16.840.1.113883.6.259 DYNAMIC) (CONF:3247-30657).
       1. This code SHALL contain exactly one [1..1] @code="1250-0" (CONF:3247-30664).
       2. This code SHALL contain exactly one [1..1] @codeSystem="2.16.840.1.113883.6.259" (CONF:3247-30665).
       3. This code SHOULD contain exactly one [1..1] @displayName="Facility Wide Inpatient" (CONF:3247-30666).

1. SHALL contain at least one [1..\*] entryRelationship (CONF:3247-30652) such that it
   1. SHALL contain exactly one [1..1] @typeCode="COMP" Has component (CodeSystem: HL7ActRelationshipType urn:oid:2.16.840.1.113883.5.1002 STATIC) (CONF:3247-30659).
   2. SHALL contain exactly one [1..1] [Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2)](#E_Facility_Transfuses_Blood_Products_Tr) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.236:2016-08-01) (CONF:3247-30658).

There *SHALL* be exactly 123 Blood Product Usage Summary Observation entryRelationships (one for each value in the value set NHSN Summary Blood Product Usage (urn:oid:2.16.840.1.114222.4.11.7353))

1. SHALL contain at least one [1..\*] entryRelationship (CONF:3247-30733) such that it
   1. SHALL contain exactly one [1..1] @typeCode="COMP" Has component (CONF:3247-30734).
   2. SHALL contain exactly one [1..1] [Blood Product Usage Summary Observation (V2)](#E_Blood_Product_Usage_Summary_Obs_V2) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.237:2016-08-01) (CONF:3247-30735).

If the facility transfused pathogen reduced apheresis platelets (i.e. the apheresis platelet total for any of codes 3514-7, 3515-4, 3516-2, 3517-0, 3518-8, or 3519-6 is > 0) then there *SHALL* be exactly 12 Pathogen Reduced Apheresis Platelet Usage Summary Observation entryRelationships (one for each value in the value set NHSN Pathogen Reduced Apheresis Platelet Usage (urn:oid:2.16.840.1.113883.10.20.5.9.5))

1. MAY contain zero or more [0..\*] entryRelationship (CONF:3247-30792) such that it
   1. SHALL contain exactly one [1..1] [Pathogen Reduced Apheresis Platelet Usage Summary Observation](#E_Pathogen_Reduced_Apheresis_Platelet_U) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.240:2016-08-01) (CONF:3247-30793).
2. SHALL contain at least one [1..\*] entryRelationship (CONF:3247-30730) such that it
   1. SHALL contain exactly one [1..1] @typeCode="COMP" Has component (CONF:3247-30731).
   2. SHALL contain exactly one [1..1] [Summary Data Observation (HV)](#E_Summary_Data_Observation_HV) (identifier: urn:hl7ii:2.16.840.1.113883.10.20.5.6.235:2015-10-01) (CONF:3247-30732).

Figure 32: Summary Encounter (HV) (V2) Example

<encounter classCode="ENC" moodCode="EVN">

<!-- Summary Encounter (HV) (V2) -->

<templateId root="2.16.840.1.113883.10.20.5.6.234" extension="2016-08-01" />

<!-- the location ID and type -->

<participant typeCode="LOC">

<participantRole classCode="SDLOC">

<id root="2.16.840.1.113883.3.117.1.1.5.1.1" extension="FACWIDEIN" />

<code codeSystem="2.16.840.1.113883.6.259" codeSystemName="HL7 HealthCareServiceLocation" code="1250-0" displayName="FACWIDEIN" />

</participantRole>

</participant>

<!-- Blood product summaries

There SHALL be exactly 102 Blood Product Usage Summary Observation

entryRelationships (one for each value in the value set NHSN Summary

Blood Product Usage (urn:oid:2.16.840.1.114222.4.11.7353))

-->

<!-- Total number of units transfused - Whole blood -->

<entryRelationship typeCode="COMP">

<observation classCode="OBS" moodCode="EVN">

<!-- [HAI] Blood Product Usage Summary Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.237" extension="2015-10-01" />

...

</observation>

</entryRelationship>

<!-- Total number of aliquots transfused - Whole blood -->

<entryRelationship typeCode="COMP">

<observation classCode="OBS" moodCode="EVN">

<!-- [HAI] Blood Product Usage Summary Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.237" extension="2015-10-01" />

...

</observation>

</entryRelationship>

<!-- Total number of Discards - Whole blood -->

<entryRelationship typeCode="COMP">

<observation classCode="OBS" moodCode="EVN">

<!-- [HAI] Blood Product Usage Summary Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.237" extension="2015-10-01" />

...

</observation>

</entryRelationship>

...

<entryRelationship typeCode="COMP">

<!-- Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation -->

<observation classCode="OBS" moodCode="EVN" negationInd="false">

<!-- [HAI R3D1.1] Facility Transfuses Blood Products Treated with

Pathogen Reduction Technology Observation -->

<templateId root="2.16.840.1.113883.10.20.5.6.236" extension="2016-08-01" />

...

</observation>

</entryRelationship>

<entryRelationship typeCode="COMP">

<observation classCode="OBS" moodCode="EVN">

<!-- Summary Data Observation (HV) -->

<templateId root="2.16.840.1.113883.10.20.5.6.235" extension="2015-10-01" />

...

</observation>

</entryRelationship>

...

</encounter>

# Template Ids in This Guide

Table 67: Template List

| Template Title | Template Type | templateId |
| --- | --- | --- |
| [HAI Population Summary Report Generic Constraints](#D_HAI_Population_Summary_Report_Generic) | document | urn:oid:2.16.840.1.113883.10.20.5.4.28 |
| [Healthcare Associated Infection Report](#D_Healthcare_Associated_Infection_Repor) | document | urn:oid:2.16.840.1.113883.10.20.5.4.25 |
| [Hemovigilance (HV) Summary Report (V2)](#D_Hemovigilance_HV_Summary_Report_V2) | document | urn:hl7ii:2.16.840.1.113883.10.20.5.49:2016-08-01 |
| [HAI Section Generic Constraints](#S_HAI_Section_Generic_Constraints) | section | urn:oid:2.16.840.1.113883.10.20.5.4.26 |
| [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) | section | urn:hl7ii:2.16.840.1.113883.10.20.5.5.57:2016-08-01 |
| [Blood Product Usage Summary Observation (V2)](#E_Blood_Product_Usage_Summary_Obs_V2) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.237:2016-08-01 |
| [Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2)](#E_Facility_Transfuses_Blood_Products_Tr) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.236:2016-08-01 |
| [ISBT Product Code Summary Observation (V2)](#E_ISBT_Product_Code_Summary_ObsV2) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01 |
| [No Hemovigilance Adverse Reactions Reported This Month Observation](#E_No_Hemovigilance_Adverse_Reactions_Re) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.232:2015-10-01 |
| [No Hemovigilance Incidents Reported This Month Observation](#E_No_Hemovigilance_Incidents_Reported_T) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.233:2015-10-01 |
| [Pathogen Reduced Apheresis Platelet Usage Summary Observation](#E_Pathogen_Reduced_Apheresis_Platelet_U) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.240:2016-08-01 |
| [Summary Data Observation (HV)](#E_Summary_Data_Observation_HV) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.235:2015-10-01 |
| [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.234:2016-08-01 |

Table 68: Template Containments

| Template Title | Template Type | templateId |
| --- | --- | --- |
| [HAI Population Summary Report Generic Constraints](#D_HAI_Population_Summary_Report_Generic) | document | urn:oid:2.16.840.1.113883.10.20.5.4.28 |
| [Healthcare Associated Infection Report](#D_Healthcare_Associated_Infection_Repor) | document | urn:oid:2.16.840.1.113883.10.20.5.4.25 |
| [Hemovigilance (HV) Summary Report (V2)](#D_Hemovigilance_HV_Summary_Report_V2) | document | urn:hl7ii:2.16.840.1.113883.10.20.5.49:2016-08-01 |
| [Summary Data Section (HV) (V2)](#S_Summary_Data_Section_HV_V2) | section | urn:hl7ii:2.16.840.1.113883.10.20.5.5.57:2016-08-01 |
| [No Hemovigilance Adverse Reactions Reported This Month Observation](#E_No_Hemovigilance_Adverse_Reactions_Re) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.232:2015-10-01 |
| [No Hemovigilance Incidents Reported This Month Observation](#E_No_Hemovigilance_Incidents_Reported_T) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.233:2015-10-01 |
| [Summary Encounter (HV) (V2)](#E_Summary_Encounter_HV_V2) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.234:2016-08-01 |
| [Summary Data Observation (HV)](#E_Summary_Data_Observation_HV) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.235:2015-10-01 |
| [Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2)](#E_Facility_Transfuses_Blood_Products_Tr) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.236:2016-08-01 |
| [Blood Product Usage Summary Observation (V2)](#E_Blood_Product_Usage_Summary_Obs_V2) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.237:2016-08-01 |
| [ISBT Product Code Summary Observation (V2)](#E_ISBT_Product_Code_Summary_ObsV2) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01 |
| [Pathogen Reduced Apheresis Platelet Usage Summary Observation](#E_Pathogen_Reduced_Apheresis_Platelet_U) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.240:2016-08-01 |
| [ISBT Product Code Summary Observation (V2)](#E_ISBT_Product_Code_Summary_ObsV2) | entry | urn:hl7ii:2.16.840.1.113883.10.20.5.6.238:2016-08-01 |
| [HAI Section Generic Constraints](#S_HAI_Section_Generic_Constraints) | section | urn:oid:2.16.840.1.113883.10.20.5.4.26 |

# Value Sets In This Guide

Table 69: Value Sets

| Name | OID | URL |
| --- | --- | --- |
| [Codes for Hemovigilance (HV) Summary Data](#Codes_for_Hemovigilance_HV_Summary_Data) | urn:oid:2.16.840.1.113883.10.20.5.9.11 | <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.10.20.5.9.11/expansion> |
| [NHSN Cryoprecipitate (24)](#NHSN_Cryoprecipitate_24) | urn:oid:2.16.840.1.114222.4.11.7315 | N/A |
| [NHSN Cryoprecipitate/Psoralen-Treated (44)](#NHSN_CryoprecipitatePsoralenTreated_44) | urn:oid:2.16.840.1.114222.4.11.7502 | N/A |
| [NHSN Cryoprecipitate/Riboflavin-Treated (45)](#NHSN_CryoprecipitateRiboflavinTreated_4) | urn:oid:2.16.840.1.114222.4.11.7503 | N/A |
| [NHSN Pathogen Reduced Apheresis Platelet Usage](#NHSN_Pathogen_Reduced_Apheresis_Platele) | urn:oid:2.16.840.1.113883.10.20.5.9.5 | <https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.10.20.5.9.5/expansion> |
| [NHSN Plasma/Apheresis/Psoralen-Treated (35)](#NHSN_PlasmaApheresisPsoralenTreated_35) | urn:oid:2.16.840.1.114222.4.11.7326 | N/A |
| [NHSN Plasma/Apheresis/Riboflavin-Treated (36)](#NHSN_PlasmaApheresisRiboflavinTreated_3) | urn:oid:2.16.840.1.114222.4.11.7327 | N/A |
| [NHSN Plasma/Apheresis/Total (23)](#NHSN_PlasmaApheresisTotal_23) | urn:oid:2.16.840.1.114222.4.11.7314 | N/A |
| [NHSN Plasma/Whole Blood Derived/Psoralen-Treated (32)](#NHSN_PlasmaWhole_Blood_DerivedPsoralenT) | urn:oid:2.16.840.1.114222.4.11.7323 | N/A |
| [NHSN Plasma/Whole Blood Derived/Riboflavin-Treated (33)](#NHSN_PlasmaWhole_Blood_DerivedRiboflavi) | urn:oid:2.16.840.1.114222.4.11.7324 | N/A |
| [NHSN Plasma/Whole Blood Derived/Total (22)](#NHSN_PlasmaWhole_Blood_DerivedTotal_22) | urn:oid:2.16.840.1.114222.4.11.7313 | N/A |
| [NHSN Platelets/Apheresis/Irradiated (19)](#NHSN_PlateletsApheresisIrradiated_19) | urn:oid:2.16.840.1.114222.4.11.7310 | N/A |
| [NHSN Platelets/Apheresis/Irradiated or Leukocyte Reduced (21)](#NHSN_PlateletsApheresisIrradiated_or_Le) | urn:oid:2.16.840.1.114222.4.11.7312 | N/A |
| [NHSN Platelets/Apheresis/Leukocyte Reduced (20)](#NHSN_PlateletsApheresisLeukocyte_Reduce) | urn:oid:2.16.840.1.114222.4.11.7311 | N/A |
| [NHSN Platelets/Apheresis/Not Irradiated or Leukocyte Reduced (18)](#NHSN_PlateletsApheresisNot_Irradiated_o) | urn:oid:2.16.840.1.114222.4.11.7309 | N/A |
| [NHSN Platelets/Apheresis/Psoralen-Treated (29)](#NHSN_PlateletsApheresisPsoralenTreated_) | urn:oid:2.16.840.1.114222.4.11.7320 | N/A |
| [NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma (46)](#NHSN_PlateletsApheresisPsoralenTreated_) | urn:oid:2.16.840.1.114222.4.11.7504 | N/A |
| [NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution (47)](#NHSN_PlateletsApheresisPsoralenTreated_) | urn:oid:2.16.840.1.114222.4.11.7505 | N/A |
| [NHSN Platelets/Apheresis/Riboflavin-Treated (30)](#NHSN_PlateletsApheresisRiboflavinTreate) | urn:oid:2.16.840.1.114222.4.11.7321 | N/A |
| [NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma (48)](#NHSN_PlateletsApheresisRiboflavinTreate) | urn:oid:2.16.840.1.114222.4.11.7506 | N/A |
| [NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution (49)](#NHSN_PlateletsApheresisRiboflavinTreate) | urn:oid:2.16.840.1.114222.4.11.7507 | N/A |
| [NHSN Platelets/Whole Blood Derived/Irradiated (14)](#NHSN_PlateletsWhole_Blood_DerivedIrradi) | urn:oid:2.16.840.1.114222.4.11.7305 | N/A |
| [NHSN Platelets/Whole Blood Derived/Irradiated and Leukocyte Reduced (16)](#NHSN_PlateletsWhole_Blood_DerivedIrradi) | urn:oid:2.16.840.1.114222.4.11.7307 | N/A |
| [NHSN Platelets/Whole Blood Derived/Leukocyte Reduced (15)](#NHSN_PlateletsWhole_Blood_DerivedLeukoc) | urn:oid:2.16.840.1.114222.4.11.7306 | N/A |
| [NHSN Platelets/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (13)](#NHSN_PlateletsWhole_Blood_DerivedNot_Ir) | urn:oid:2.16.840.1.114222.4.11.7304 | N/A |
| [NHSN Platelets/Whole Blood Derived/Psoralen-Treated (26)](#NHSN_PlateletsWhole_Blood_DerivedPsoral) | urn:oid:2.16.840.1.114222.4.11.7317 | N/A |
| [NHSN Platelets/Whole Blood Derived/Riboflavin-Treated (27)](#NHSN_PlateletsWhole_Blood_DerivedRibofl) | urn:oid:2.16.840.1.114222.4.11.7318 | N/A |
| [NHSN Red Blood Cells/Apheresis/Irradiated (9)](#NHSN_Red_Blood_CellsApheresisIrradiated) | urn:oid:2.16.840.1.114222.4.11.7300 | N/A |
| [NHSN Red Blood Cells/Apheresis/Irradiated or Leukocyte Reduced (11)](#NHSN_Red_Blood_CellsApheresisIrradiated) | urn:oid:2.16.840.1.114222.4.11.7302 | N/A |
| [NHSN Red Blood Cells/Apheresis/Leukocyte Reduced (10)](#NHSN_Red_Blood_CellsApheresisLeukocyte_) | urn:oid:2.16.840.1.114222.4.11.7301 | N/A |
| [NHSN Red Blood Cells/Apheresis/Not Irradiated or Leukocyte Reduced (8)](#NHSN_Red_Blood_CellsApheresisNot_Irradi) | urn:oid:2.16.840.1.114222.4.11.7299 | N/A |
| [NHSN Red Blood Cells/Apheresis/Riboflavin-Treated (42)](#NHSN_Red_Blood_CellsApheresisRiboflavin) | urn:oid:2.16.840.1.114222.4.11.7501 | N/A |
| [NHSN Red Blood Cells/Apheresis/S-303-Treated (41)](#NHSN_Red_Blood_CellsApheresisS303Treate) | urn:oid:2.16.840.1.114222.4.11.7500 | N/A |
| [NHSN Red Blood Cells/Whole Blood Derived/Irradiated (4)](#NHSN_Red_Blood_CellsWhole_Blood_Derived) | urn:oid:2.16.840.1.114222.4.11.7295 | N/A |
| [NHSN Red Blood Cells/Whole Blood Derived/Irradiated and Leukocyte Reduced (6)](#NHSN_Red_Blood_CellsWhole_Blood_Derived) | urn:oid:2.16.840.1.114222.4.11.7297 | N/A |
| [NHSN Red Blood Cells/Whole Blood Derived/Leukocyte Reduced (5)](#NHSN_Red_Blood_CellsWhole_Blood_Derived) | urn:oid:2.16.840.1.114222.4.11.7296 | N/A |
| [NHSN Red Blood Cells/Whole Blood Derived/Not Irradiated or Leukocyte Reduced (3)](#NHSN_Red_Blood_CellsWhole_Blood_Derived) | urn:oid:2.16.840.1.114222.4.11.7294 | N/A |
| [NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated](#NHSN_Red_Blood_CellsWhole_Blood_Derived) | urn:oid:2.16.840.1.114222.4.11.7499 | N/A |
| [NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated](#NHSN_Red_Blood_CellsWhole_Blood_Derived) | urn:oid:2.16.840.1.114222.4.11.7498 | N/A |
| [NHSN Whole Blood Total (1)](#NHSN_Whole_Blood_Total_1) | urn:oid:2.16.840.1.114222.4.11.7292 | N/A |
| [NHSNPopulationSummaryReportTypeCode](#NHSNPopulationSummaryReportTypeCode) | urn:oid:2.16.840.1.114222.4.11.3595 | <https://vsac.nlm.nih.gov/valueset/2.16.840.1.114222.4.11.3595/expansion> |
| [NHSNSummaryBloodProductUsage](#NHSNSummaryBloodProductUsage) | urn:oid:2.16.840.1.114222.4.11.7353 | <https://vsac.nlm.nih.gov/valueset/2.16.840.1.114222.4.11.7353/expansion> |

# Code Systems in This Guide

Table 70: Code Systems

| Name | OID |
| --- | --- |
| Administrative Gender | urn:oid:2.16.840.1.113883.5.1 |
| cdcNHSN | urn:oid:2.16.840.1.113883.6.277 |
| Healthcare Provider Taxonomy (HIPAA) | urn:oid:2.16.840.1.113883.6.101 |
| HL7ActClass | urn:oid:2.16.840.1.113883.5.6 |
| HL7ActCode | urn:oid:2.16.840.1.113883.5.4 |
| HL7ActMood | urn:oid:2.16.840.1.113883.5.1001 |
| HL7ActRelationshipType | urn:oid:2.16.840.1.113883.5.1002 |
| HL7ActStatus | urn:oid:2.16.840.1.113883.5.14 |
| HL7Confidentiality | urn:oid:2.16.840.1.113883.5.25 |
| HL7ContextControl | urn:oid:2.16.840.1.113883.5.1057 |
| HL7EntityClass | urn:oid:2.16.840.1.113883.5.41 |
| HL7NullFlavor | urn:oid:2.16.840.1.113883.5.1008 |
| HL7ParticipationType | urn:oid:2.16.840.1.113883.5.90 |
| HL7RoleClass | urn:oid:2.16.840.1.113883.5.110 |
| HSLOC | urn:oid:2.16.840.1.113883.6.259 |
| ISBT-128 | urn:oid:2.16.840.1.113883.6.18 |
| LOINC | urn:oid:2.16.840.1.113883.6.1 |
| ObservationInterpretation | urn:oid:2.16.840.1.113883.5.83 |
| Race & Ethnicity - CDC | urn:oid:2.16.840.1.113883.6.238 |
| RxNorm | urn:oid:2.16.840.1.113883.6.88 |
| SNOMED CT | urn:oid:2.16.840.1.113883.6.96 |

# Changes from Previous Version

None

1. HL7 CDA R2. <http://www.hl7.org/implement/standards/product_brief.cfm?product_id=7> [↑](#footnote-ref-1)
2. *HL7 V3: Refinement, Constraint and Localization.* <http://www.hl7.org/v3ballot/html/infrastructure/conformance/conformance.htm> [↑](#footnote-ref-2)
3. *HL7 Version 3 Publishing Facilitator's Guide.* <http://www.hl7.org/v3ballot/html/help/pfg/pfg.htm> [↑](#footnote-ref-3)
4. *HL7 Version 3 Interoperability Standards*. [http://www.hl7.org/memonly/downloads/v3edition.cfm - V32010](http://www.hl7.org/memonly/downloads/v3edition.cfm#V32010) [↑](#footnote-ref-4)
5. W3C, *XML Path Language.* <http://www.w3.org/TR/xpath/> [↑](#footnote-ref-5)